QuidelOrtho 10-K 23 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 15, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	QUIDEL CORP /DE/
Entity Central Index Key	353,569
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	QDEL
Amendment Flag	false
Entity Common Stock, Shares Outstanding		32,271,420
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 646,268,331

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 191,471	$ 200,895
Accounts receivable, net	18,398	34,466
Inventories	26,388	24,763
Deferred tax asset—current	0	8,316
Restricted cash	63	3,127
Prepaid expenses and other current assets	4,344	2,914
Total current assets	240,664	274,481
Property, plant and equipment, net	52,547	49,226
Goodwill	80,730	80,748
Intangible assets, net	31,833	41,890
Other non-current assets	731	1,066
Total assets	406,505	447,411
Current liabilities:
Accounts payable	8,675	12,421
Accrued payroll and related expenses	9,627	8,349
Current portion of lease obligation	585	509
Current portion of contingent consideration	1,286	733
Deferred grant revenue	3,658	6,330
Other current liabilities	6,999	8,043
Total current liabilities	30,830	36,385
Long-term debt	143,297	137,958
Lease obligation, net of current portion	4,032	4,617
Contingent consideration—non-current	4,230	5,023
Deferred tax liability—non-current	1,970	14,890
Income taxes payable	910	806
Deferred rent	2,296	2,228
Other non-current liabilities	$ 264	$ 493
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at December 31, 2015 and 2014	$ 0	$ 0
Common stock, $.001 par value per share; 97,500 shares authorized; 33,323 and 34,433 shares issued and outstanding at December 31, 2015 and 2014, respectively	33	34
Additional paid-in capital	209,121	229,374
Accumulated other comprehensive loss	(31)	(29)
Retained earnings	9,553	15,632
Total stockholders’ equity	218,676	245,011
Total liabilities and stockholders’ equity	$ 406,505	$ 447,411

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share	$ 0.001	$ 0.001
Common stock, shares authorized	97,500,000	50,000,000
Common stock, shares issued	33,323,000	34,433,000
Common stock, shares outstanding	33,323,000	34,433,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Total revenues	$ 196,129	$ 184,158	$ 177,325
Costs and expenses
Cost of sales (excludes amortization of intangible assets of $6,341, $6,283, and $6,079, respectively)	71,688	74,180	66,976
Research and development	35,514	37,913	34,186
Sales and marketing	47,886	43,076	35,744
General and administrative	29,447	25,811	25,581
Amortization of intangible assets from acquired businesses and technology	8,856	8,828	8,171
Impairment loss	0	3,558	0
Facility restructuring charge	0	0	1,825
Total costs and expenses	193,391	193,366	172,483
Operating income (loss)	2,738	(9,208)	4,842
Interest expense, net	(12,035)	(1,775)	(1,408)
(Loss) income before benefit for income taxes	(9,297)	(10,983)	3,434
Benefit for income taxes	(3,218)	(3,909)	(3,956)
Net (loss) income	$ (6,079)	$ (7,074)	$ 7,390
Basic (loss) earnings per share	$ (0.18)	$ (0.21)	$ 0.22
Diluted (loss) earnings per share	$ (0.18)	$ (0.21)	$ 0.21
Shares used in basic per share calculations	34,104	34,451	33,836
Shares used in diluted per share calculations	34,104	34,451	34,947

Consolidated Statements of Ope5

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Amortization of intangible assets	$ 6,079	$ 6,341	$ 6,283

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (6,079)	$ (7,074)	$ 7,390
Other comprehensive (loss) income, net of tax
Changes in cumulative translation adjustment	(2)	(47)	18
Comprehensive (loss) income	$ (6,081)	$ (7,121)	$ 7,408

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional paid-in capital [Member]	Accumulated other comprehensive income (loss) [Member]	Retained earnings [Member]
Beginning Balance at Dec. 31, 2012	$ 199,780	$ 33	$ 184,431	$ 0	$ 15,316
Beginning Balance, shares at Dec. 31, 2012		33,451,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	8,385	$ 1	8,384
Issuance of common stock under equity compensation plans, shares		708,000
Excess tax benefit from share-based compensation	2,346		2,346
Stock-based compensation expense	8,017		8,017
Repurchases of common stock	(2,157)		(2,157)
Repurchases of common stock	(2,157)
Repurchase of common stock, shares		(86,000)
Changes in cumulative translation adjustment, net of tax	18			18
Net (loss) income	7,390				7,390
Ending Balance at Dec. 31, 2013	$ 223,779	$ 34	201,021	18	22,706
Ending Balance, shares at Dec. 31, 2013		34,073,000
Preferred stock, shares outstanding	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	$ 5,471	$ 0	5,471
Issuance of common stock under equity compensation plans, shares		428,000
Convertible senior notes, equity portion, net of tax and issuance costs	29,758		29,758
Tax impact from the issuance of convertible senior notes	(11,362)		(11,362)
Stock-based compensation expense	6,442		6,442
Repurchases of common stock	(1,956)		(1,956)
Repurchases of common stock	(1,956)
Repurchase of common stock, shares		(68,000)
Changes in cumulative translation adjustment, net of tax	(47)			(47)
Net (loss) income	(7,074)				(7,074)
Ending Balance at Dec. 31, 2014	$ 245,011	$ 34	229,374	(29)	15,632
Ending Balance, shares at Dec. 31, 2014		34,433,000
Preferred stock, shares outstanding	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity compensation plans	$ 3,318		3,318
Issuance of common stock under equity compensation plans, shares		308,000
Excess tax benefit from share-based compensation	571		571
Stock-based compensation expense	6,791		6,791
Repurchases of common stock	(30,400)	$ (1)	(30,933)
Repurchases of common stock	(30,934)
Repurchase of common stock, shares		(1,418,000)
Changes in cumulative translation adjustment, net of tax	(2)			(2)
Net (loss) income	(6,079)				(6,079)
Ending Balance at Dec. 31, 2015	$ 218,676	$ 33	$ 209,121	$ (31)	$ 9,553
Ending Balance, shares at Dec. 31, 2015		33,323,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,434,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
OPERATING ACTIVITIES
Net (loss) income	$ (6,079)	$ (7,074)	$ 7,390
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation, amortization and other	23,386	28,365	24,896
Stock-based compensation expense	7,419	6,724	8,771
Impairment loss	0	3,558	0
Amortization of debt discount and deferred issuance costs	5,664	629	337
Change in fair value of acquisition contingencies	(88)	(910)	80
Change in deferred tax assets and liabilities	(4,027)	(2,744)	(1,928)
Excess tax benefit from share-based compensation	(571)	0	(2,346)
Changes in assets and liabilities:
Accounts receivable	16,060	(4,547)	2,911
Inventories	(1,637)	2,862	(11,975)
Prepaid expenses and other current and non-current assets	(1,039)	787	(388)
Restricted cash	3,064	(2,158)	1,187
Accounts payable	(3,082)	4,380	(651)
Accrued payroll and related expenses	1,061	1,247	1,055
Income taxes payable	(64)	(1,036)	(3,523)
Deferred grant revenue	(2,672)	4,301	(127)
Other current and non-current liabilities	(1,086)	1,302	(7)
Net cash provided by operating activities	36,309	35,686	25,682
INVESTING ACTIVITIES
Acquisitions of property and equipment	(16,968)	(11,149)	(20,821)
Acquisition of BioHelix, net of cash acquired	0	0	(9,184)
Acquisition of AnDiaTec	0	0	(2,250)
Acquisition of intangibles	(64)	(92)	(1,680)
Net cash used for investing activities	(17,032)	(11,241)	(33,935)
FINANCING ACTIVITIES
Proceeds from issuance of Convertible Senior Notes	0	172,500	0
Proceeds from issuance of common stock, net of cancellations	2,911	4,781	7,928
Payments of debt issuance costs	(365)	(4,712)	0
Excess tax benefit from share-based compensation	571	0	2,346
Payments on lease obligation	(509)	(441)	(380)
Repurchases of common stock	(30,934)	(1,956)	(2,157)
Payments on line of credit	0	0	(5,000)
Payments on acquisition contingencies	(129)	(2,112)	(947)
Payment for acquisition holdback	(229)	0	0
Net cash (used for) provided by financing activities	(28,684)	168,060	1,790
Effect of exchange rate changes on cash	(17)	2	(5)
Net (decrease) increase in cash and cash equivalents	(9,424)	192,507	(6,468)
Cash and cash equivalents, beginning of period	200,895	8,388	14,856
Cash and cash equivalents, at end of period	191,471	200,895	8,388
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for interest	6,998	981	1,807
Cash paid during the period for income taxes	1,922	327	2,211
NON-CASH INVESTING ACTIVITIES
Purchase of capital equipment by incurring current liabilities	239	900	172
Lease incentive for tenant improvements	0	0	1,658
NON-CASH FINANCING ACTIVITIES
Decrease of accrued payroll and related expenses upon issuance of common stock	408	663	456
Debt issuance costs by incurring current liabilities	$ 0	$ 365	$ 0

Company Operations and Summary

Company Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Company Operations and Summary of Significant Accounting Policies	Company Operations and Summary of Significant Accounting Policies Quidel Corporation (the “Company”) commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets rapid diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics and wellness screening centers. The Company markets its products in the U.S. through a network of national and regional distributors, and a direct sales force. Internationally, the Company sells and markets through distributor arrangements. The accompanying consolidated financial statements of the Company and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the U.S. Consolidation— The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less. Accounts Receivable— The Company sells its products directly to hospitals and reference laboratories in the U.S. as well as to distributors in the U.S. and internationally (see Note 7). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company’s reserves primarily consist of amounts related to cash discounts, volume discounts and contract rebates. The balance of accounts receivable is net of reserves of $7.5 million and $8.2 million at December 31, 2015 and 2014 , respectively. Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consists principally of trade accounts receivable. The Company invests its cash equivalents primarily in money market funds. Cash equivalents are maintained with high quality institutions. The Company’s trade accounts receivable are primarily derived from sales to medical distributors, hospitals and reference laboratories in the U.S. (see Note 7). The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored by evaluation of collection history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable. Inventories— Inventories are stated at the lower of cost (first-in, first-out method) or market. The Company reviews the components of its inventory on a quarterly basis for excess, obsolete and impaired inventory and makes appropriate dispositions as obsolete stock is identified. Inventories consisted of the following, net of reserves of $0.7 million and $2.2 million at December 31, 2015 and 2014 , respectively (in thousands): December 31, 2015 2014 Raw materials $ 10,289 $ 10,472 Work-in-process (materials, labor and overhead) 7,441 6,834 Finished goods (materials, labor and overhead) 8,658 7,457 Total inventories $ 26,388 $ 24,763 Property, Plant and Equipment— Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets ( three to 15 years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the estimated useful lives of the assets. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $12.7 million , $10.3 million and $7.9 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Maintenance and minor repairs are charged to operations as incurred. Property, plant and equipment consisted of the following (in thousands): December 31, 2015 2014 Equipment, furniture and fixtures $ 59,736 $ 64,233 Building and improvements 33,048 32,074 Leased instruments 18,280 12,395 Land 1,080 1,080 Total property, plant and equipment, gross 112,144 109,782 Less: accumulated depreciation and amortization (59,597 ) (60,556 ) Total property, plant and equipment, net $ 52,547 $ 49,226 Goodwill and Intangible Assets— Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for software development costs and indefinite-lived intangibles such as goodwill and in-process research and development. Software development costs associated with software to be sold, leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized. The capitalized cost is amortized on a straight-line basis over the estimated product life or on the ratio of current revenues to total projected product revenues, whichever is greater. Amortization expense related to the capitalized software costs was $0.6 million , $0.6 million and $0.3 million for the years ended December 31, 2015 , 2014 and 2013, respectively. Goodwill and intangible assets consisted of the following (dollar amounts in thousands): December 31, 2015 December 31, 2014 Description Weighted-average useful life (years) Gross assets Accumulated amortization Net Gross assets Accumulated amortization Net Goodwill Indefinite $ 84,179 $ (3,449 ) $ 80,730 $ 84,197 $ (3,449 ) $ 80,748 Purchased technology 8.4 52,560 (34,911 ) 17,649 51,870 (28,570 ) 23,300 Customer relationships 7.6 7,171 (4,972 ) 2,199 7,214 (3,978 ) 3,236 In-process research and development Indefinite — — — 690 — 690 License agreements 10.6 5,512 (2,542 ) 2,970 34,324 (30,050 ) 4,274 Patent and trademark costs 12.3 10,530 (2,588 ) 7,942 10,530 (1,725 ) 8,805 Software development costs 5 2,913 (1,840 ) 1,073 2,849 (1,264 ) 1,585 Total goodwill and intangible assets $ 162,865 $ (50,302 ) $ 112,563 $ 191,674 $ (69,036 ) $ 122,638 Amortization expense was $10.2 million , $17.4 million and $16.6 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Included in this amortization expense amount for 2015 , 2014 and 2013 is $0.7 million , $8.0 million , and $8.0 million , respectively, of amortization for licensed technology recorded in cost of sales. This amount is related to the purchase of a license pursuant to the Alere Amendment as discussed in Note 6. The intangible asset associated with this intangible was fully amortized in the first quarter of 2015. The expected future annual amortization expense of the Company’s intangible assets is as follows (in thousands): For the years ending December 31, Amortization expense 2016 $ 9,288 2017 9,000 2018 3,430 2019 2,175 2020 1,796 Thereafter 6,144 Total $ 31,833 The Company recorded a $1.6 million impairment loss related to a discontinued research and development named Project Stella (Bobcat) during the third quarter of 2014. See further discussion in Note 10. The Company completed its annual evaluation for impairment of goodwill and determined that no impairment of goodwill existed as of December 31, 2015 . Impairment of Long-Lived Assets— The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the total book value of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and the eventual disposition are less than its carrying amount. An impairment loss is equal to the excess of the book value of an asset over its determined fair value. For the year ended December 31, 2014, the Company recorded a $1.5 million impairment loss on software development costs related to Project Stella. See further discussion in Note 10. The Company recorded no impairment losses for the years ended December 31, 2015 and 2013. Other current liabilities— Other current liabilities consisted of the following (in thousands): December 31, 2015 2014 Customer incentives $ 4,030 $ 4,729 Accrued research and development costs 773 990 Other 2,196 2,324 Total other current liabilities $ 6,999 $ 8,043 Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. See Note 2 for additional discussion of the Convertible Senior Notes issued in December 2014. Revenue Recognition— The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts that are estimated at the time of sale, and are largely driven by various customer program offerings, including special pricing agreements, promotions and other volume-based incentives. Revenue from product sales are recorded upon passage of title and risk of loss to the customer. Passage of title to the product and recognition of revenue occurs upon delivery to the customer when sales terms are free on board (“FOB”) destination and at the time of shipment when the sales terms are FOB shipping point and there is no right of return. A portion of product sales includes revenues for diagnostic kits, which are utilized on leased instrument systems under the Company’s “reagent rental” program. The reagent rental program provides customers the right to use the instruments at no separate cost to the customer in consideration for a multi-year agreement to purchase annual minimum amounts of consumables (“reagents” or “diagnostic kits”). When an instrument is placed with a customer under a reagent rental agreement, the Company retains title to the equipment and it remains capitalized on the Company’s Consolidated Balance Sheets as property and equipment. The instrument is depreciated on a straight-line basis over the life of the instrument. Depreciation expense is recorded in cost of sales included in the Consolidated Statements of Operations. The reagent rental agreements represent one unit of accounting as the instrument and consumables (reagents) are interdependent in producing a diagnostic result and neither has a stand-alone value with respect to these agreements. No revenue is recognized at the time of instrument placement. All revenue is recognized when the title and risk of loss for the diagnostic kits have passed to the customer. Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. The Company also earns income from the licensing of technology. The Company earns income from grants for research and commercialization activities. On November 6, 2012, the Company was awarded a milestone-based grant totaling up to $8.3 million from the Bill and Melinda Gates Foundation to develop, manufacture and validate a quantitative, low-cost, nucleic acid assay for HIV drug treatment monitoring on the integrated Savanna MDx platform for use in limited resource settings. Upon execution of the grant agreement, the Company received $2.6 million to fund subsequent research and development activities and received milestone payments totaling $2.5 million in 2013. On September 10, 2014, the Company entered into an amended grant agreement with the Bill and Melinda Gates Foundation for additional funding of up to $12.6 million in order to accelerate the development of the Savanna MDx platform in the developing world. Upon execution of the amended grant agreement, the Company received $10.6 million in cash. The Company received a payment of $2.4 million in April 2015 based on milestone achievements for both the original and the amended grant agreements and expects to receive the remaining milestone payments of up to $2.8 million in 2016. Under the original and amended grant agreements, the Company recognizes grant revenue on the basis of the lesser of the amount recognized on a proportional performance basis or the amount of cash payments that are non-refundable as of the end of each reporting period. For the years ended December 31, 2015 , 2014 and 2013 , we recognized $5.1 million , $6.3 million and $2.6 million as grant revenue, respectively. Cash payments received are restricted as to use until expenditures contemplated in the grant are incurred or committed. Therefore, the Company classified $0.1 million and $3.1 million of funds received from the Bill and Melinda Gates Foundation as restricted cash as of December 31, 2015 and 2014 , respectively. In addition, the Company classified $3.7 million and $6.3 million as deferred grant revenue as of December 31, 2015 and 2014 , respectively. Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred. Collaborative Arrangement— In July 2012, the Company entered into a collaborative arrangement with Life Technologies Corporation for the development of molecular assays. ASC Topic 808, Collaborative Arrangements (“ASC Topic 808”), defines a collaborative arrangement as an arrangement where the parties are active participants and have exposure to significant risks. The Company accounted for the joint development and commercialization activities with the third-party as a joint risk sharing collaboration in accordance with ASC Topic 808. Payments to the Company from Life Technologies Corporation totaled $0.4 million in 2014 and $1.4 million in 2013. The Company received no payments in 2015 and does not expect additional payments as the development efforts are complete. The reimbursement represents 50% of project development costs based upon mutually agreed upon project plans for each molecular assay. In connection with the collaboration agreement, the Company also entered into a manufacturing and supply agreement with the same third party. As part of that agreement, and upon commercialization, the Company will manufacture and sell assays to the third party at cost plus 20% . Additionally, the Company will receive 40% of the gross margin for sales from the third party to the end customer. In March 2013, the Company entered into a six year instrument supply agreement (the “March 2013 Agreement”) with Life Technologies Corporation. Pursuant to the March 2013 Agreement, the Company paid $0.8 million for distribution rights to sell Life Technologies Corporation’s QuantStudio™ DX diagnostic laboratory instrument for use in the infectious disease field, along with the assays developed under the collaborative agreement. The distribution rights are included in intangible assets on the Consolidated Balance Sheets and are being amortized on a straight-line basis over the contractual term of six years. Product Shipment Costs— Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Operations. Shipping and handling costs were $3.9 million , $3.8 million and $4.1 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Advertising Costs— Advertising costs are expensed as incurred. Advertising costs were $0.7 million , $0.4 million and $0.7 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Deferred Rent— Rent expense is recorded on a straight-line basis over the term of the lease. The difference between rent expense and amounts paid under the lease agreement are recorded as deferred rent. Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense. Fair Value of Financial Instruments — The Company uses the fair value hierarchy established in ASC Topic 820 , Fair Value Measurements and Disclosures, that requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of the Company’s financial instruments, including cash, receivables, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature. Product Warranty —The Company generally sells products with a limited product warranty and certain limited indemnifications. Due to product testing, the short time between product shipment and the detection and correction of product failures and a low historical rate of payments on indemnification claims, the historical activity and the related expense were not significant for the fiscal years presented. Stock-Based Compensation —Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. Compensation expense for restricted stock units (RSUs) is measured at the grant date and recognized ratably over the vesting period. The fair value of RSUs is determined based on the closing market price of the Company’s common stock on the grant date. Computation of (Loss) Earnings Per Share —For the twelve months ended December 31, 2015 and 2014 , basic loss per share was computed by dividing net loss by the weighted-average number of common shares outstanding, including restricted stock units vested during the period. Diluted earnings per share (“EPS”) reflects the potential dilution that could occur if the earnings were divided by the weighted-average number of common shares and potentially dilutive common shares from outstanding stock options as well as unvested restricted stock units. Potential dilutive common shares were calculated using the treasury stock method and represent incremental shares issuable upon exercise of the Company’s outstanding stock options and unvested restricted stock units. For the twelve months ended December 31, 2015 and 2014 , there were no differences between the number of common shares used for the basic and diluted EPS computation because the Company incurred a net loss and the effect would be anti-dilutive. Stock options and shares of restricted stock that would have been included in the diluted EPS calculation if the Company had earnings amounted to 1.0 million and 1.1 million for the twelve months ended December 31, 2015 and 2014 , respectively. Additionally, stock options are excluded from the calculation of diluted EPS when the combined exercise price, unrecognized stock-based compensation and expected tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. Stock options totaling 1.9 million and 1.0 million for the twelve months ended December 31, 2015 and 2014 , respectively, were not included in the computation of diluted EPS because the exercise of such options would be anti-dilutive. As discussed in Note 2, the Company issued Convertible Senior Notes (“Convertible Senior Notes”) in December 2014. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in cash or shares of common stock (“conversion premium”). No conversion premium existed as of December 31, 2015 and 2014 , therefore, there was no dilutive impact from the Convertible Senior Notes to diluted EPS. For the twelve months ended December 31, 2013 , diluted net income per share was reported based on the more dilutive of the treasury stock or the two-class method. Under the two-class method, net income is allocated to common stock and participating securities. For the twelve months ended December 31, 2013 , the Company’s unvested restricted stock awards and certain unvested restricted stock units met the definition of participating securities. Basic net income per share under the two-class method was computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share under the two-class method was computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation and expected tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. Stock options totaling 0.5 million for the twelve months ended December 31, 2013 were not included in the computation of diluted EPS because the exercise of such options would be anti-dilutive. The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2013 (in thousands, except per share amounts): 2013 Basic net income per share: Net income $ 7,390 Less: income allocated to participating securities (17 ) Net income allocated to common stockholders $ 7,373 Weighted average common shares outstanding — basic 33,836 Net income per share — basic $ 0.22 Diluted net income per share: Net income $ 7,390 Less: income allocated to participating securities (16 ) Net income allocated to common stockholders $ 7,374 Weighted average common shares outstanding — basic 33,836 Dilutive securities 1,111 Weighted average common shares outstanding — diluted 34,947 Net income per share — diluted $ 0.21 Comprehensive (Loss) Income —Comprehensive (loss) income includes unrealized gains and losses excluded from the Company’s Consolidated Statements of Operations. Facility Restructuring — In 2013, the Company announced a plan to move its manufacturing operations in Santa Clara, California to Athens, Ohio. Termination benefits for those employees who choose not to relocate are accounted for in accordance with ASC Topic 712, Compensation – Nonretirement Postemployment Benefits , and are recorded when it is probable that employees will be entitled to benefits and the amounts can be reasonably estimated. Estimates of termination benefits are based on the frequency of past termination benefits and the similarity of benefits under the current plan and prior plans. Facility related costs are accounted for in accordance with ASC Topic 420, Exit or Disposal Cost Obligations , and are recorded when the liability is incurred. The Company recorded a charge of $1.8 million during the year ended December 31, 2013, which included employee termination benefits and impairment charges related to the facility lease. The Company recorded no restructuring charges during the years ended December 31, 2015 and 2014. Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Accounting Periods —Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ends are January 3, 2016, December 28, 2014 and December 29, 2013. For ease of reference, the calendar quarter end dates are used herein. Changes to the recording of prior period freight billed to customers from sales and marketing expenses to revenues —The Company corrected immaterial errors in the classification of freight billed to customers of $1.5 million and $1.9 million for the years ended December 31, 2014 and 2013 , respectively, from sales and marketing expense as previously reported in the Consolidated Statements of Operations to revenues. The adjustments did not impact net income (loss) as previously reported or any prior amounts reported on the Consolidated Balance Sheets, Statements of Cash Flows, Statements of Comprehensive (Loss) Income or Statements of Stockholders' Equity. Management evaluated the materiality both qualitatively and quantitatively and determined it was not material to the previously reported consolidated financial statements. Change in Accounting Principle —The Company historically presented deferred debt issuance costs, or fees related to directly issuing debt, as assets on the Consolidated Balance Sheets. During the first quarter of 2015, the Company adopted guidance codified in ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs . The guidance simplifies the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs is not affected. Therefore, these costs will continue to be amortized as interest expense using the effective interest method pursuant to ASC 835-30-35-2 through 35-3. The Company elected to early adopt the requirements of ASU 2015-03 effective the first quarter ended March 31, 2015 and applied this guidance retrospectively to all prior periods presented in the Company's financial statements. The reclassification does not impact net income (loss) as previously reported or any prior amounts reported on the Consolidated Statements of Comprehensive Income (Loss) or the Consolidated Statements of Cash Flows. The following table presents the effect of the retrospective application of this change in accounting principle on the Company’s Consolidated Balance Sheets as of December 31, 2014: Consolidated Balance Sheets (in thousands) As Reported December 31, 2014 Effect of Change in Accounting Principle After change in Accounting Principle ASSETS Current assets: Prepaid expenses and other current assets $ 3,554 $ (640 ) $ 2,914 Total current assets 275,121 (640 ) 274,481 Other non-current assets 4,565 (3,499 ) 1,066 Total assets $ 451,550 $ (4,139 ) $ 447,411 LIABILITIES AND STOCKHOLDERS’ EQUITY Long-term debt 142,097 (4,139 ) 137,958 Total liabilities and stockholders’ equity $ 451,550 $ (4,139 ) $ 447,411 Recent Accounting Pronouncements —In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance codified in Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition . This guidance is intended to improve and converge with international standards relating to the financial reporting requirements for revenue from contracts with customers. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current authoritative guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The original guidance was effective for annual reporting periods beginning after December 15, 2016. However, in July 2015, the FASB deferred by one year the effective dates of the new revenue recognition standard for entities reporting under GAAP. As a result, the standard will be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2018. In August 2014, the FASB issued guidance codified in ASU 2014-15 (Subtopic 205-40), Presentation of Financial Statements - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). Management will be required to make this evaluation for both annual and interim reporting periods and will make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in ASC Topic 450, Contingencies . The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company does not expect this guidance to have a significant impact on the consolidated financial statements and expects to adopt the standard for the annual reporting period ended December 31, 2016. In February 2015, the FASB issued guidance codified in ASU 2015-02 (Topic 810), Consolidation - Amendments to the Consolidation Analysis . The guidance affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. Specifically, the guidance amends (i) the identification of variable interests (fees paid to a decision

Debt

Debt	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt	Debt 3.25% Convertible Senior Notes due 2020 In December 2014, the Company issued $172.5 million aggregate principal amount of 3.25% Convertible Senior Notes due 2020. Debt issuance costs of approximately $5.1 million were primarily comprised of underwriters fees, legal, accounting, and other professional fees of which $4.2 million were capitalized and are recorded as a reduction to long-term debt and are being amortized using the effective interest method to interest expense over the six -year term of the Convertible Senior Notes. The remaining $0.9 million of debt issuance costs were allocated as a component of equity in additional paid-in capital. Deferred issuance costs related to the Convertible Senior Notes were $3.5 million and $4.1 million as of December 31, 2015 and 2014 , respectively. The Convertible Senior Notes will be convertible into cash, shares of common stock, or a combination of cash and shares of common stock based on an initial conversion rate, subject to adjustment, of 31.1891 shares per $1,000 principal amount of the Convertible Senior Notes (which represents an initial conversion price of approximately $32.06 per share) on the business day immediately preceding September 15, 2020. This conversion will occur in the following circumstances and to the following extent: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2015, if the last reported sales price of the Company's common stock, for at least 20 trading days (whether or not consecutive) in the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price of the notes in effect on each applicable trading day; (2) during the five consecutive business day period following any five consecutive trading day period in which the trading price per 1,000 principal amount of the Convertible Senior Note for each such trading day was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such day; or (3) upon the occurrence of specified events described in the indenture for the Convertible Senior Notes. On or after September 15, 2020 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their notes for conversion at any time, regardless of the foregoing circumstances. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the “principal portion” of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25 -day observation period as described in the indenture for the Convertible Senior Notes. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume weighted average price (“VWAP”) of the Company’s common stock. The “share amount” is the cumulative “daily share amount” during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. The Company pays 3.25% interest per annum on the principal amount of the Convertible Senior Notes semi-annually in arrears in cash on June 15 and December 15 of each year. The Convertible Senior Notes mature on December 15, 2020. During the year ended December 31, 2015 , the Company recorded total interest expense of $10.9 million related to the Convertible Senior Notes of which $5.3 million related to the amortization of the debt discount and issuance costs and $5.6 million related to the coupon due semi-annually. During the year ended December 31, 2014, the Company recorded total interest expense of $0.6 million related to the Convertible Senior Notes of which $0.3 million related to the amortization of the debt discount and issuance costs and $0.3 million related to the coupon due semi-annually. If a fundamental change, as defined in the indenture for the Convertible Senior Notes, such as an acquisition, merger, or liquidation of the Company, occurs prior to the maturity date, subject to certain limitations, holders of the Convertible Senior Notes may require the Company to repurchase all or a portion of their Convertible Senior Notes for cash at a repurchase price equal to 100% of the principal amount of the Convertible Senior Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the repurchase date. The Company accounts separately for the liability and equity components of the Convertible Senior Notes in accordance with authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. The guidance requires the carrying amount of the liability component to be estimated by measuring the fair value of a similar liability that does not have an associated conversion feature. Because the Company has no outstanding non-convertible public debt, the Company determined that senior, unsecured corporate bonds traded on the market represent a similar liability to the Convertible Senior Notes without the conversion option. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry with similar credit ratings and with similar maturity, the Company estimated the implied interest rate of its Convertible Senior Notes to be 6.9%, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, which were defined as Level 2 observable inputs. The estimated implied interest rate was applied to the Convertible Senior Notes, which resulted in a fair value of the liability component of $141.9 million upon issuance, calculated as the present value of implied future payments based on the $172.5 million aggregate principal amount. The $30.7 million difference between the cash proceeds of $172.5 million and the estimated fair value of the liability component was recorded in additional paid-in capital as the Convertible Senior Notes were not considered redeemable. As a policy election under applicable guidance related to the calculation of diluted net earnings per share, the Company elected the combination settlement method as its stated settlement policy and applied the treasury stock method in the calculation of dilutive impact of the Convertible Senior Notes. The Convertible Senior Notes were not convertible as of the years ended December 31, 2015 and 2014 and had no dilutive impact during the years ended December 31, 2015 and 2014 . If the Convertible Senior Notes were converted as of December 31, 2015 , the if-converted value would not exceed the principal amount. The following table summarizes information about the equity and liability components of the Convertible Senior Notes (dollars in thousands). The fair values of the respective notes outstanding were measured based on quoted market prices. December 31, 2015 2014 Principal amount of Convertible Senior Notes outstanding $ 172,500 $ 172,500 Unamortized discount of liability component (25,703 ) (30,403 ) Unamortized deferred issuance costs (1) (3,500 ) (4,139 ) Net carrying amount of liability component 143,297 137,958 Less: current portion — — Long-term debt $ 143,297 $ 137,958 Carrying value of equity component, net of issuance costs $ 29,758 $ 29,758 Fair value of outstanding Convertible Senior Notes (2) $ 170,120 $ 190,613 Remaining amortization period of discount on the liability component 5 years 6 years (1) Includes reclassification of $0.6 million from prepaid expenses and other current assets and $3.5 million from other non-current assets as of December 31, 2014. (2) Subsequent to the issuance of the financial statements for the year ended December 31, 2014, the Company discovered an error in its disclosure of the fair value of outstanding convertible senior notes. The fair value of the Convertible Senior Notes at December 31, 2014 was $190.6 million instead of the amount originally disclosed in the Company’s Annual Report on Form 10-K, which inappropriately reflected only the book value of the long-term debt component of the Convertible Senior Notes, which was $142.1 million . The revision in the disclosure of fair value for the Convertible Senior Notes did not impact net loss as previously reported or any prior amounts reported on the Consolidated Balance Sheets, Statements of Operations, Statements of Comprehensive (Loss) Income, Statements of Cash Flows or Statements of Stockholders' Equity as of and for the year ended December 31, 2014. Line of Credit On August 10, 2012, the Company entered into an amended and restated $140.0 million senior secured syndicated credit facility (the “Senior Credit Facility”), which matures on August 10, 2017 . As part of this amendment, the Company incurred an additional $1.0 million in deferred financing costs related to the Senior Credit Facility. Deferred financing costs are amortized on a straight-line basis over the term of the Senior Credit Facility. As of December 31, 2015 the Company had deferred financing costs related to the Senior Credit Facility of $0.2 million included as a portion of other non-current assets and $0.3 million included as a portion of prepaid expenses and other current assets. As of December 31, 2014 , $0.5 million of deferred financing costs were included as a portion of other non-current assets and $0.3 million were included as a portion of prepaid expenses and other current assets. The Senior Credit Facility bears interest at either the London Interbank Offered Rate (“LIBOR”) or the base rate, plus, in each case, an applicable margin. The base rate is equal to the highest of (i) the lender’s prime rate, (ii) the federal funds rate plus one-half of one percent and (iii) LIBOR plus one percent . The applicable margin is generally determined in accordance with a performance pricing grid based on the Company’s leverage ratio and ranges from 1.25% to 2.50% for LIBOR rate loans and from 0.25% to 1.50% for base rate loans. The agreement governing the Senior Credit Facility includes certain customary limitations, including among others: limitations on liens; on mergers, consolidations and dispositions of assets; on debt; on dividends, stock redemptions and the redemption and/or prepayment of other debt; on investments (including loans and advances) and acquisitions; and on transactions with affiliates. The Company is also subject to financial covenants which include a funded debt to adjusted EBITDA ratio (as defined in the Senior Credit Facility, with adjusted EBITDA generally calculated as earnings before, among other adjustments, interest, taxes, depreciation, amortization, and stock-based compensation) not to exceed 3 :1 as of the end of each fiscal quarter, and an interest coverage ratio of not less than 3 :1 as of the end of each fiscal quarter. Funded debt is defined as outstanding borrowings on the Senior Credit Facility plus Convertible Senior Notes, less the Company’s domestic cash and cash equivalents in excess of $15.0 million . The Senior Credit Facility is secured by substantially all present and future domestic assets and properties of the Company and is senior to the Convertible Senior Notes. As of December 31, 2015 , the Company had no borrowings outstanding and had $126.1 million available under the Senior Credit Facility. The Company’s ability to borrow under the Senior Credit Facility fluctuates from time to time due to, among other factors, the Company’s borrowings under the facility and its funded debt to adjusted EBITDA ratio. As of December 31, 2014 , the Company had no borrowings outstanding under the Senior Credit Facility. As of December 31, 2015 and 2014 , the Company was in compliance with all financial covenants.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Significant components of the (benefit) provision for income taxes are as follows (in thousands): December 31, 2015 2014 2013 Current: Federal $ 948 $ 61 $ (565 ) State 399 (1,294 ) 810 Foreign 41 69 18 Total current provision (benefit) 1,388 (1,164 ) 263 Deferred: Federal (4,624 ) (5,267 ) (2,584 ) State — 2,488 (1,635 ) Foreign 18 34 — Total deferred benefit (4,606 ) (2,745 ) (4,219 ) Benefit for income taxes $ (3,218 ) $ (3,909 ) $ (3,956 ) The Company’s (loss) income before (benefit) provision for income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2015 2014 2013 United States $ (9,480 ) $ (11,328 ) $ 3,364 Foreign 183 345 70 (Loss) income before benefit for income taxes $ (9,297 ) $ (10,983 ) $ 3,434 Significant components of the Company’s deferred tax assets as of December 31, 2015 and 2014 are shown below (in thousands). December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 1,199 $ 2,236 Intangible assets 3,574 3,366 Sale-leaseback, net 1,224 1,424 Allowance for returns and discounts 4,308 4,574 Stock based compensation 9,884 8,255 Tax credit carryforwards 2,341 2,060 Other, net 5,200 4,472 Total deferred tax assets 27,730 26,387 Valuation allowance for deferred tax assets (3,087 ) (2,331 ) Total deferred tax assets, net of valuation allowance 24,643 24,056 Deferred tax liabilities: Convertible Senior Notes (9,474 ) (11,267 ) Intangible assets (9,977 ) (12,939 ) Property, plant and equipment (7,162 ) (6,424 ) Total deferred tax liabilities (26,613 ) (30,630 ) Net deferred tax assets and liabilities $ (1,970 ) $ (6,574 ) Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative before-tax loss incurred over the three-year periods ended December 31, 2015 and 2014 . Such objective evidence limits the ability to consider other subjective evidence such as our projections for future profitability. On the basis of this evaluation, as of December 31, 2014 , we recorded a valuation allowance of $2.3 million and increased the valuation allowance by $0.8 million to $3.1 million as of December 31, 2015 . This valuation allowance represents the portion of the deferred tax asset that management could no longer conclude was more likely or not to be realized. The amount of the deferred tax assets considered realizable, however, could be adjusted in the future based on changes in available evidence, such as if objective negative evidence in the form of continued net losses are no longer present and additional weight may be given to subjective evidence such as the Company's projections for profitability. The Company recognizes excess tax benefits associated with the exercise of stock options directly to stockholders’ equity only when realized. Accordingly, deferred tax assets are not recognized for net operating loss (“NOL”) carryforwards resulting from excess tax benefits. As of December 31, 2015 and 2014 , deferred tax assets do not include $1.3 million and $1.5 million , respectively, of these excess tax benefits from employee stock option exercises that are a component of the Company’s NOL and tax credit carryforwards. Additional paid-in capital will be increased up to an additional $1.3 million if such excess tax benefits are realized. As of December 31, 2015 , the Company had federal NOL carryforwards of approximately $1.5 million which will begin to expire in 2018, unless previously utilized. The Company also had state NOLs of approximately $17.6 million which will begin to expire in 2026, unless previously utilized. The Company has federal research credits of $2.7 million which will begin to expire on December 31, 2032 , unless previously utilized. The Company has federal alternative minimum tax credits of $0.5 million which do not expire. The Company also has gross state research credits of $7.9 million , of which $7.7 million do not expire. The remaining $0.2 million begin to expire in 2027, unless previously utilized. Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, the Company’s use of its NOL and research credit carryforwards may be limited as a result of cumulative changes in ownership of more than 50% over a three -year period. The benefit for income taxes reconciles to the amount computed by applying the federal statutory rate to income (loss) before taxes as follows (in thousands): Year ended December 31, 2015 2014 2013 Tax (benefit) expense at statutory tax rate (3,254 ) (3,844 ) 1,214 State (benefit) taxes, net of federal tax (benefit) (235 ) (151 ) 63 Permanent differences 157 70 (76 ) Federal and state research credits—current year (722 ) (765 ) (1,046 ) Federal research credits - prior year — — (527 ) (Release) accrual of uncertain tax positions 101 (21 ) 369 Expiration of statutes for uncertain tax positions — (953 ) (3,452 ) Impact of change in federal and state tax rate on revaluing deferred tax assets 56 110 (581 ) Change in valuation allowance 756 2,331 — Acquisition related adjustments — (485 ) — Other (77 ) (201 ) 80 Benefit for income taxes (3,218 ) (3,909 ) (3,956 ) On December 18, 2015, the Protecting Americans from Tax Hikes Act was signed into law reinstating the federal research and development credit for 2015. Accordingly, we recorded the benefit related to the 2015 federal research and development credit of approximately $0.4 million in the fourth quarter of 2015. On January 3, 2013, the American Taxpayer Relief Act of 2012 was signed into law reinstating the federal research and development credit for the 2012 and 2013 years. Accordingly, we recorded the benefit related to the 2012 federal research and development credit of approximately $0.5 million in the first quarter of 2013. The Company considers earnings of its non-U.S. subsidiaries to be indefinitely reinvested in those operations. As of December 31, 2015 , the Company has not made a provision for U.S. or additional foreign withholding taxes on approximately $0.4 million of the excess of the amount for financial reporting over the tax basis of investments in foreign subsidiaries that is indefinitely reinvested. Generally, such amounts become subject to U.S. taxation upon the remittance of dividends and under certain other circumstances. It is not practicable to estimate the amount of deferred tax liability related to investments in these foreign subsidiaries. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While the Company believes that it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. The following table summarizes the activity related to the Company’s for unrecognized tax benefits (in thousands): Year ended December 31, 2015 2014 2013 Beginning balance $ 7,065 $ 7,765 $ 9,051 (Decreases) increases related to prior year tax positions (12 ) (68 ) 773 Increases related to current year tax positions 631 642 1,019 Decreases due to settlements — (42 ) — Expiration of the statute of limitations for the assessment of taxes — (1,232 ) (3,078 ) Ending balance $ 7,684 $ 7,065 $ 7,765 As of December 31, 2015 and 2014 , the unrecognized tax benefits of $7.7 million and $7.1 million , respectively, of which $5.6 million and $5.2 million , respectively, would reduce the Company’s annual effective tax rate, subject to the valuation allowance. The Company does not anticipate any significant decreases in its unrecognized tax benefits over the next 12 months. The Company's policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense. The Company has accrued approximately $0.2 million of interest and penalties associated with uncertain tax positions as of December 31, 2015 . Interest expense, net of accrued interest (reversed), in 2015 , 2014 , and 2013 was approximately $0.1 million , $(0.2) million , and $(0.3) million , respectively. The Company is subject to periodic audits by domestic and foreign tax authorities. During 2013, the Company was notified by the Internal Revenue Service that the Congressional Joint Committee of Taxation had completed its review and proposed no changes to the Company’s tax returns filed for the tax periods 2008 through 2010. As a result, the Company released tax reserves and related interest of approximately $3.5 million . During 2014, the Company released tax reserves and related interest of approximately $1.0 million , net of federal income tax benefits, related to the expiration of the statute of limitation on assessment for certain state matters. Due to the carryforward of unutilized net operating loss and credit carryovers, the Company's federal tax years from 2009 and forward and state tax years 2001 and forward are subject to examination by tax authorities. The Company believes that it has appropriate support for the income tax positions taken on its tax returns and that its accruals for tax liabilities are adequate for all open years based on an assessment of many factors, including past experience and interpretations of tax law applied to the facts of each matter.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock. The Company’s certificate of incorporation, as amended, authorizes the issuance of up to five million preferred shares. The Board of Directors is authorized to fix the number of shares of any series of preferred stock and to determine the designation of such shares. However, the amended certificate of incorporation specifies the initial series and the rights of that series. No shares of preferred stock were outstanding as of December 31, 2015 , 2014 or 2013. Equity Incentive Plan. The Company grants stock options, restricted stock units (RSUs) and performance-based restricted stock units (PSUs) to employees and non-employee directors under its Amended and Restated 2010 Equity Incentive Plan (the “2010 Plan”) and previously granted stock options under the Amended and Restated 2001 Equity Incentive Plan (the "2001 Plan"). The 2001 Plan was terminated at the time of adoption of the 2010 Plan, but the terminated Plan continues to govern outstanding options granted thereunder. The Company has stock options and RSUs outstanding, which were issued under each of these equity incentive plans to certain employees and directors. Stock options granted under these plans have terms ranging up to ten years, have exercise prices ranging from $8.50 to $27.91 per share, and generally vest over four years. As of December 31, 2015 , approximately 1.4 million shares remained available for grant under the 2010 Plan. Restricted Stock. The Company grants time-based RSUs and PSUs to certain officers, directors and management. Until the restrictions lapse, ownership of the affected RSUs granted to the Company’s officers is conditional upon continuous employment with the Company. For the years ended December 31, 2015 , 2014 and 2013 , the Company granted approximately 0.2 million , 0.1 million and 0.1 million shares, respectively, of RSUs to officers and management, which have a time-based four -year vesting provision. A portion of the RSUs granted in 2012 and 2011 was performance-based and vesting was tied to achievement of specific Company goals in 2014 and 2013, respectively. For purposes of measuring compensation expense, the amount of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with the PSUs requires judgment in assessing the probability of meeting the performance goals, as well as defined criteria for assessing achievement of the performance-related goals. The grant date of the PSUs takes place when the grant is authorized and the specific achievement goals are communicated. The communication date of the performance goals can impact the valuation and associated expense of the PSUs. The PSUs granted in March 2011 included a three -year vesting cliff based on the achievement of a performance metric tied to earnings per share for the year ended December 31, 2013 . During the fourth quarter ended December 31, 2013 , the Compensation Committee of the Board of Directors amended the performance metric to include adjustments for certain items, some of which are non-recurring. This resulted in a modification of the original award and the Company recorded additional stock-based compensation expense of $1.9 million for the year ended December 31, 2013 . The PSUs granted in March 2012 included a three -year vesting cliff based on the achievement of a performance metric tied to earnings per share for the year ended December 31, 2014 . During the fourth quarter ended December 31, 2014 , the Compensation Committee of the Board of Directors amended the performance metric to include adjustments for certain items, some of which are non-recurring. This resulted in a modification of the original award and the Company recorded additional stock-based compensation expense of $0.3 million for the year ended December 31, 2014 . The PSUs granted in March 2011 and March 2012 were released in March 2014 and March 2015, respectively, as performance metrics were achieved. There are no PSUs outstanding as of December 31, 2015 . During the years ended December 31, 2015 , 2014 and 2013 , RSUs were granted to certain members of the Board of Directors in lieu of cash compensation as a part of the Company’s non-employee director’s deferred compensation program. The compensation expense associated with these RSU grants were $0.5 million , $0.4 million and $0.4 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Employee Deferred Bonus Compensation Program. For the year ended December 31, 2015 and 2014 , certain employees of the Company were eligible to participate in the Company’s deferred bonus compensation program with respect to any payments received under the Company’s cash incentive plan. Participating employees could elect to receive 50% or 100% of the cash value of their cash bonus in the form of fully vested, restricted stock units plus an additional premium as additional restricted stock units, issued under the 2010 Plan. The premium restricted stock units are subject to a one -year vesting requirement from the date of issuance. The additional premium will be determined based on the length of time of the deferral period selected by the participating employee as follows: (i) if one year from the date of grant, a premium of 10% on the amount deferred, (ii) if two years from the date of grant, a premium of 20% on the amount deferred, or (iii) if four years from the date of grant, a premium of 30% on the amount deferred. Employee Stock Purchase Plan. Under the Company’s 1983 Employee Stock Purchase Plan (the “ESPP”), full-time employees are allowed to purchase common stock through payroll deductions (which cannot exceed 10% of the employee’s compensation) at the lower of 85% of fair market value at the beginning or end of each six -month purchase period. As of December 31, 2015 , 1,131,493 shares had been sold under the Plan, leaving 118,507 shares available for future issuance. Share Repurchase Program. On January 25, 2016, our Board of Directors authorized an amendment to extend our previously announced stock repurchase program. The Board of Directors has authorized the Company to repurchase up to an aggregate of $50.0 million in shares of our common stock under our stock repurchase program. Any shares of common stock repurchased under this program will no longer be deemed outstanding upon repurchase and will be returned to the pool of authorized shares. During the year ended December 31, 2015 , 1,397,000 shares of outstanding common stock were repurchased under the Company's previously announced share repurchase program for approximately $30.4 million . At December 31, 2015 , $19.6 million remains available under this plan. The repurchase program will expire on January 25, 2018 unless extended by our Board of Directors. On December 20, 2013, the Company repurchased 37,709 shares of common stock based on the closing price of the Company’s stock on the date of the transaction from a Member of the Board of Directors, in exchange for payment for the aggregate exercise of 76,687 stock options. The stock option exercise is included in the issuance of common stock under equity compensation plans and the repurchase is included in repurchases of common stock presented in the Consolidated Statements of Stockholders’ Equity. Shares Reserved for Future Issuance. At December 31, 2015 , approximately 5.9 million shares of common stock were reserved under the Company’s equity incentive plans and 118,507 shares were reserved for purchases under the ESPP.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation For the years ended December 31, 2015 , 2014 and 2013 stock-based compensation expense was $7.4 million , $6.7 million and $8.8 million , respectively, of which $4.7 million , $4.3 million and $4.0 million , respectively, related to stock options and $2.0 million , $2.1 million and $4.0 million , respectively, related to RSUs and PSUs. For the years ended December 31, 2015 , 2014 and 2013 the Company recorded $0.7 million , $0.3 million and $0.8 million in stock-based compensation expense, respectively, associated with the deferred bonus compensation program, described in Note 4. During the years ended December 31, 2015 , 2014 and 2013 , $0.6 million , $0.3 million and $0.7 million , respectively, were initially recorded as a component of accrued payroll and related expenses. Stock-based compensation expense related to stock options, RSUs and PSUs was as follows (in thousands): Year ended December 31, 2015 2014 2013 Cost of sales $ 581 $ 609 $ 815 Research and development 734 1,062 1,912 Sales and marketing 1,554 1,059 821 General and administrative 4,550 3,994 5,223 $ 7,419 $ 6,724 $ 8,771 Stock-based compensation expense capitalized to inventory and compensation expense related to the Company’s ESPP were not material for the years ended December 31, 2015 , 2014 and 2013 . Stock Options Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option award. For stock options with graded vesting, the Company ensures that the cumulative amount of compensation expense recognized at the end of any reporting period at least equals the portion of the stock option that has vested at that date. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants: Year ended December 31, 2015 2014 2013 Risk-free interest rate 1.50 % 1.59 % 0.86 % Expected option life (in years) 6.24 5.78 5.53 Volatility rate 40 % 42 % 44 % Dividend rate — % — % — % The computation of the expected option life is based on a weighted-average calculation combining the average life of options that have already been exercised and post-vest cancellations with the estimated life of the remaining vested and unexercised options. The expected volatility is based on the historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. Treasury yield curve over the expected term of the option. The Company has never paid any cash dividends on its common stock, and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes option valuation model. The Company’s estimated forfeiture rate is based on its historical experience and future expectations. The Company’s determination of fair value is affected by the Company’s stock price as well as a number of assumptions that require judgment. The weighted-average fair value per share was $9.46 , $10.96 and $9.19 for options granted during the years ended December 31, 2015 , 2014 and 2013 , respectively. The total intrinsic value was $1.6 million , $2.8 million and $8.1 million for options exercised during the years ended December 31, 2015 , 2014 and 2013 , respectively. As of December 31, 2015 , total unrecognized compensation expense related to stock options was approximately $6.6 million and the related weighted-average period over which it is expected to be recognized is approximately 2.2 years. The maximum contractual term of the Company’s stock options is ten years. A summary of the status of stock option activity for the years ended December 31, 2013 , 2014 and 2015 is as follows (in thousands, except price data and years): Number of Shares Weighted- average exercise price per share Weighted- average remaining contractual term (in years) Aggregate intrinsic value Outstanding at January 1, 2013 3,600 $ 13.15 Granted 529 22.36 Exercised (642 ) 12.16 Cancelled (13 ) 10.61 Outstanding at December 31, 2013 3,474 14.74 Granted 559 26.63 Exercised (251 ) 13.67 Cancelled (175 ) 20.63 Outstanding at December 31, 2014 3,607 16.37 Granted 659 23.15 Exercised (168 ) 12.30 Cancelled (131 ) 23.41 Outstanding at December 31, 2015 3,967 $ 17.44 5.54 $ 19,225 Vested and expected to vest at December 31, 2015 3,827 $ 17.20 5.52 $ 19,192 Exercisable at December 31, 2015 2,657 $ 14.37 4.16 $ 18,503 Available for future grant at December 31, 2015 1,434 Restricted Stock Units The fair value of RSUs is determined based on the closing market price of the Company’s common stock on the grant date. The Company grants both time-based restricted stock named RSUs and performance-based restricted stock named PSUs. Compensation expense for time-based RSUs is measured at the grant date and recognized ratably over the vesting period. A portion of the restricted stock granted in 2012 and 2011 was performance-based and vesting is tied to achievement of specific Company goals in 2014 and 2013, respectively. For purposes of measuring compensation expense, the amount of shares ultimately expected to vest is estimated at each reporting date based on management’s expectations regarding the relevant performance criteria. The recognition of compensation expense associated with PSUs requires judgment in assessing the probability of meeting the performance goals, as well as defined criteria for assessing achievement of the performance-related goals. The grant date of the PSUs takes place when the grant is authorized and the specific achievement goals are communicated. The communication date of the performance goals can impact the valuation and associated expense of the PSU. See further discussion of amended performance metrics and the impact to stock-based compensation expense in Note 4. A summary of the status of stock awards activity for the years ended December 31, 2013 , 2014 and 2015 is as follows (in thousands, except price data): Shares Weighted-average grant date fair value Non-vested at January 1, 2013 522 $ 13.87 Granted 74 23.53 Vested (141 ) 23.43 Forfeited (1 ) 15.26 Non-vested at December 31, 2013 454 16.22 Granted 145 25.73 Vested (174 ) 28.27 Forfeited (23 ) 18.19 Non-vested at December 31, 2014 402 14.84 Granted 171 22.79 Vested (96 ) 18.01 Forfeited (18 ) 22.87 Non-vested at December 31, 2015 459 $ 21.61 In 2015 , 2014 and 2013 , the Company issued approximately 0.1 million restricted share units each year in exchange for the deferred bonus liability of $0.4 million , $0.7 million and $0.4 million , respectively. The total amount of unrecognized compensation expense related to non-vested stock awards as of December 31, 2015 was approximately $3.0 million , which is expected to be recognized over a weighted-average period of approximately 2.8 years.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2015 are as follows (in thousands): Years ending December 31, Operating Leases Lease obligation 2016 $ 2,383 $ 922 2017 1,885 931 2018 1,644 940 2019 1,669 950 2020 1,684 959 Thereafter 1,971 1,079 Total minimum lease payments $ 11,236 5,781 Less: amount representing interest (1,164 ) Present value of lease obligation 4,617 Less: current portion (585 ) Long-term lease obligation $ 4,032 Operating Leases —Rent expense under operating leases totaled approximately $2.3 million for the year ended December 31, 2015 , $3.3 million for the year ended December 31, 2014 and $2.3 million for the year ended December 31, 2013 . In the fourth quarter of 2013 , the Company entered into a lease for approximately 30,000 square feet of office space and moved the executive and administrative functions into this facility in the second quarter of 2014. The lease expires in 2022 with options to extend the lease for two additional five -year periods. This operating lease included a lease incentive for tenant improvements of $1.7 million which has been included as a leasehold improvement in property, plant and equipment and as deferred rent in other current liabilities and non-current deferred rent. McKellar Lease Obligation —During 1999, the Company completed a sale and leaseback transaction of its San Diego facility. The facility was sold for $15.0 million , of which $3.8 million was capital contributed by the Company. The sale was an all cash transaction, netting the Company approximately $7.0 million . The Company is a 25% limited partner in the partnership that acquired the facility. The transaction was deemed a financing transaction under the guidance in ASC Topic 840-40, Accounting for Sales of Real Estate . The assets sold remain on the books of the Company and will continue to be depreciated over the estimated useful life. In December 2009, the Company amended the terms of its lease agreement which had no significant impact on the Company’s financial statements. The amended terms included a new ten -year lease term through December 31, 2019 , with options to extend the lease for up to three additional five -year periods. In the fourth quarter of 2015, the Company amended the terms of its lease agreement to extend the lease term through December 31, 2020. The options to extend the lease for up to three additional five-year periods commence at the new lease term date of December 31, 2020. The Company is amortizing the lease obligation over the new lease term. As the Company accounts for the lease as a financing transaction, the Company adjusted the implied interest rate so that the existing lease obligation is amortized to December 31, 2020. The Company has determined that the partnership is a variable interest entity (VIE). The Company is not, however, the primary beneficiary of the VIE as it does not absorb the majority of the partnership’s expected losses or receive a majority of the partnership’s residual returns. The Company made lease payments to the partnership of approximately $1.1 million for each of the three years ended December 31, 2015 , 2014 and 2013 . Purchase Commitments The Company has $4.0 million in firm purchase commitments with respect to planned capital expenditures as of December 31, 2015 . Legal The Company is involved in various claims and litigation matters from time to time in the ordinary course of business. Management believes that all such current legal actions, in the aggregate, will not have a material adverse effect on the Company. The Company also maintains insurance, including coverage for product liability claims, in amounts which management believes are appropriate given the nature of its business. At December 31, 2015 and 2014 , the Company had $0.2 million and $0.3 million , respectively, accrued as a liability for various legal matters where the Company deemed the liability probable and estimable. Licensing Arrangements On September 27, 2011, the Company entered into the Second Amendment (the “Amendment”) to Quidel/Inverness Settlement Agreement dated April 27, 2005 (the “Agreement”), as amended by an Addendum dated June 19, 2006, with Alere Inc. (formerly known as Inverness Medical Innovations, Inc.) (“Alere”). The Amendment, which was effective as of April 1, 2011, amended certain royalty and other provisions in the Agreement and enabled the Company to “buy-down” and “buy-out” its future royalty obligation under the Agreement for payments totaling $29.5 million . Under the Amendment, the Company made an initial cash payment of $13.8 million to Alere in September 2011 in connection with a buy-down of the Company’s royalty obligations for the period beginning July 1, 2011. In addition, the Company exercised its buy-out right for any remaining future royalty obligation by exercising the Royalty Termination Option (as defined in the Amendment) in January 2012, thereby terminating the Company’s obligation to pay future royalties under the Agreement in exchange for a fixed cash payment in the amount of $15.7 million less $1.0 million of specified third quarter 2011 royalties. This amount was paid in February 2012. In conjunction with Financial Accounting Standards Board Accounting Standard Update No. 2009-05, Fair Value Measurements and Disclosures (Topic 820), the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales to settle royalty claims. In determining the fair value allocation between the intangible asset licensed technology and the one-time charge to cost of sales, the Company assessed the past and estimated future revenue streams related to present and future products that use the patents that were subject to the Amendment. The effective life and related amortization of the licensed technology was based on the higher of the percentage of usage or the straight-line method. This percentage of usage was determined using the revenues generated from products covered by the patents that were subject to the Amendment. The terms of the Amendment provide for an estimated useful life of 3.5 years for this asset. The Company recorded $0.7 million of amortization expense in 2015 and $8.0 million in both 2014 and 2013, included as a portion of cost of sales. As of December 31, 2015, this intangible asset has been fully amortized. In addition to the royalty agreement noted above, the Company has entered into various other licensing and royalty agreements, which largely require payments based on specified product sales as well as the achievement of specified milestones. The Company had royalty and license expenses relating to those agreements of approximately $0.5 million , $0.9 million and $1.0 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Research and Development Agreements The Company has entered into various research and development agreements that provide it with rights to develop, manufacture and market products using the intellectual property and technology of its collaborative partners. Under the terms of certain of these agreements, the Company is required to make periodic payments based on achievement of certain milestones or resource expenditures. These milestones generally include achievement of prototype assays, validation lots and clinical trials. At December 31, 2015 , total future commitments under the terms of these agreements are estimated at $4.2 million . The commitments will fluctuate as we agree to new phases of development under the existing arrangements. Contingent Consideration In conjunction with the acquisition of BioHelix Corporation (“BioHelix”) in May 2013, the Company agreed to contingent consideration ranging from $5.0 million to $13.0 million upon achievement of certain research and development milestones and revenue targets through 2018. During 2014, the Company disbursed research and development milestone payments totaling $2.1 million and all payments related to research and development milestones had been disbursed as of December 31, 2014. Payments of $0.1 million and $49,000 related to the revenue royalty earn-out were disbursed during the twelve months ended December 31, 2015 and 2014 , respectively. The fair value of the remaining contingent consideration related to the revenue royalty earn-out to be settled in cash is estimated based on the Monte Carlo Simulation Model. Due to changes in the estimated payments and a shorter discounting period, the fair value of the contingent consideration liabilities changed, resulting in gains of $21,000 and $0.8 million recorded to cost of sales in the Consolidated Statements of Operations during the years ended December 31, 2015 and 2014, respectively. As of December 31, 2015 , the current portion of the contingent consideration is $1.3 million and the non-current portion of the contingent consideration is $4.1 million . In August 2013, the Company completed a business combination accomplished by acquiring the assets of AnDiaTec GmbH & Co. KG (“AnDiaTec”), a privately-held, diagnostics company, based in Germany. The Company agreed to contingent consideration of up to €0.5 million ( $0.5 million based on the December 31, 2015 currency conversion rate) upon achievement of certain revenue targets through 2018. The fair value of the remaining contingent consideration related to the revenue royalty earn-out to be settled in cash is estimated based on the Monte Carlo Simulation Model. Due to changes in the estimated payments and a shorter discounting period, the fair value of the contingent consideration liabilities changed, resulting in a $67,000 gain recorded to cost of sales in the Consolidated Statements of Operations during the year ended December 31, 2015 . As of December 31, 2015 the current portion of the contingent consideration is $35,000 and the non-current portion of the contingent consideration is $0.1 million . In addition, the Company agreed to pay the founder of AnDiaTec contingent payments of up to €3.0 million ( $3.3 million based on the December 31, 2015 currency conversion rate) upon achievement of certain research and development milestones, subject to continued employment. The Company paid $1.7 million and $0.9 million for the achievement of agreed upon research and development milestones during the twelve months ended December 31, 2015 and 2014 , respectively. These costs are recorded as compensation expense included in research and development expense in the Consolidated Statements of Operations.

Industry and Geographic Informa

Industry and Geographic Information	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Industry and Geographic Information	Industry and Geographic Information The Company operates in one reportable segment. Sales to customers outside the U.S. represented 14% , 13% and 13% of total revenue for the years ended December 31, 2015 , 2014 and 2013 , respectively. As of December 31, 2015 and 2014 , balances due from foreign customers, in U.S. dollars, were $5.6 million and $5.5 million , respectively. The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2015 2014 2013 Customer: A 20 % 19 % 19 % B 17 % 18 % 16 % C 11 % 11 % 8 % 48 % 48 % 43 % As of December 31, 2015 and 2014 , accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $12.0 million and $23.7 million , respectively. The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue year ended December 31, 2015 2014 2015 2014 2013 Domestic $ 52,426 $ 49,052 $ 168,809 $ 159,845 $ 154,626 Foreign 121 174 27,320 24,313 22,699 $ 52,547 $ 49,226 $ 196,129 $ 184,158 $ 177,325 Consolidated net product revenues by disease state are as follows (in thousands): Year ended December 31, 2015 2014 2013 Infectious disease $ 141,857 $ 130,416 $ 128,079 Women’s health 37,161 34,332 33,328 Gastrointestinal disease 7,224 7,414 6,622 Royalty, license fees and grant revenue 6,189 7,681 3,917 Other 3,698 4,315 5,379 $ 196,129 $ 184,158 $ 177,325

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2015 December 31, 2014 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents 133,147 — — 133,147 3,057 — — 3,057 Total assets measured at fair value $ 133,147 $ — $ — $ 133,147 $ 3,057 $ — $ — $ 3,057 Liabilities: Contingent consideration — — 5,516 5,516 — — 5,756 5,756 Total liabilities measured at fair value $ — $ — $ 5,516 $ 5,516 $ — $ — $ 5,756 $ 5,756 There were no transfers of assets or liabilities between Level 1, Level 2 and Level 3 categories of the fair value hierarchy during the years ended December 31, 2015 and 2014 . The Company used Level 1 inputs to determine the fair value of its cash equivalents, which primarily consist of funds held in a money market account, and as such, the carrying value of cash equivalents approximates fair value. As of December 31, 2015 and 2014 , the carrying value of cash equivalents was $133.1 million and $3.1 million , respectively. The Company assesses the fair value of contingent consideration to be settled in cash related to acquisitions using the Monte Carlo Simulation Model for the royalty earn-out portions of the contingent liability and probability weighted models for the research and development earn-out. These are Level 3 measurements. Significant assumptions used in the measurement include probabilities of achieving the remaining milestones and the discount rates, which depend on the milestone risk profiles. Due to changes in the estimated payments and a shorter discounting period, the fair value of the contingent consideration liabilities changed during the years ended December 31, 2015 and 2014 . These changes resulted in a $0.1 million gain and $0.9 million gain recorded to cost of sales in the Consolidated Statements of Operations during the years ended December 31, 2015 and 2014 , respectively. Changes in estimated fair value of contingent consideration liabilities from December 31, 2014 through December 31, 2015 are as follows (in thousands): Contingent consideration liability (Level 3 measurement) Balance at December 31, 2014 $ 5,756 Cash payments (129 ) Net gain recorded for fair value adjustments (88 ) Unrealized gain on foreign currency translation (23 ) Balance at December 31, 2015 $ 5,516

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	Employee Benefit Plan The Company has a defined contribution 401(k) plan (the “401(k) Plan”) covering all employees who are eligible to join the 401(k) Plan upon employment. Employee contributions are subject to a maximum limit by federal law. This Plan includes an employer match of 50% on the first 6% of pay contributed by the employee. The Company contributed approximately $1.3 million , $1.1 million and $0.9 million to the 401(k) Plan during the years ended December 31, 2015 , 2014 and 2013 , respectively.

Impairment Loss

Impairment Loss	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment Loss	Impairment Loss The Company originally acquired certain automated direct fluorescent antibody cell analyzer technology as part of its DHI acquisition in 2010. This technology and the related program named "Project Stella" or "Bobcat" continued in development or evaluation (both the technology and associated instrument system) since the acquisition. During the third quarter of 2014, the Company evaluated the potential cash flows related to Project Stella as well as potential sale of the assets or joint development opportunities with third parties. As a result of those activities, the Company identified indicators of impairment related to the Project Stella assets. These assets included $1.5 million of software development costs, $1.6 million of in-process research and development, and $0.3 million in manufacturing line costs. During 2014, the Company completed an evaluation of the recoverability of the assets, which included cash flow analyses as well as pursuing a potential sale of the assets to third parties. Based on the analyses, the Company determined the carrying value was not recoverable and an impairment loss was measured by comparing the carrying value to the estimated fair value of the assets. The fair value of the Project Stella assets was estimated utilizing the discounted cash flow analysis. As a result, the Company recognized an impairment loss of $3.4 million in the third quarter of 2014, included in the Company's Consolidated Statements of Operations. Additionally, $0.2 million was included in the impairment loss related to the expense to terminate a manufacturing contract with a third party to manufacture Project Stella instruments. The Company recorded no further impairment charges for the year ended December 31, 2014 and recorded no impairment charges for the year ended December 31, 2015.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (unaudited)	Selected Quarterly Financial Data (unaudited) First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2015 Total revenues (1) $ 61,701 $ 35,204 $ 46,812 $ 52,412 Cost of sales (excludes amortization of intangible assets) 21,112 15,493 16,961 18,122 Gross profit (2) 39,018 18,121 28,261 32,700 Total costs and expenses (1) 53,012 45,029 45,600 49,750 Net (loss) income 3,991 (8,931 ) (762 ) (377 ) Basic net (loss) earnings per share (3) 0.12 (0.26 ) (0.02 ) (0.01 ) Diluted net (loss) earnings per share (3) 0.11 (0.26 ) (0.02 ) (0.01 ) 2014 Total revenues (1) $ 47,129 $ 31,883 $ 41,193 $ 63,953 Cost of sales (excludes amortization of intangible assets) 20,247 15,902 16,768 21,263 Gross profit (2) 25,311 14,410 22,854 41,120 Total costs and expenses (1) 49,146 41,868 51,314 51,038 Net income (loss) (1,512 ) (6,908 ) (5,767 ) 7,113 Basic net earnings (loss) per share (3) (0.04 ) (0.20 ) (0.17 ) 0.21 Diluted net earnings (loss) per share (3) (0.04 ) (0.20 ) (0.17 ) 0.20 (1) Includes reclassification of freight billed to customers from sales and marketing expense to revenue of $0.4 million and $0.3 million for the first and second quarters of 2015, respectively, and $0.5 million , $0.4 million , $0.3 million , and $0.4 million for the first, second, third, and fourth quarters of 2014, respectively. (2) Included in 2015 and 2014 quarterly gross profit is amortization of intangible assets of $1.6 million , $1.6 million , $1.6 million and $1.5 million for the first quarter, second quarter, third quarter and fourth quarter, respectively. (3) Basic and diluted EPS amounts in each quarter are computed using the weighted-average number of shares outstanding during that quarter, while basic and diluted EPS for the full year is computed using the weighted-average number of shares outstanding during the year. Therefore, the sum of the four quarters’ basic or diluted EPS may not equal the full year basic or diluted EPS.

Consolidated Valuation and Qual

Consolidated Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2015
Valuation and Qualifying Accounts [Abstract]
Consolidated Valuation and Qualifying Accounts	SCHEDULE II QUIDEL CORPORATION CONSOLIDATED VALUATION AND QUALIFYING ACCOUNTS Description Balance at beginning of period Additions charged to expense or as reductions to revenue (1) Deductions (2) Balance at end of period (in thousands) Year ended December 31, 2015 Accounts receivable allowance $ 8,221 $ 31,532 $ (32,265 ) $ 7,488 Year ended December 31, 2014: Accounts receivable allowance $ 5,790 $ 23,447 $ (21,016 ) $ 8,221 Year ended December 31, 2013: Accounts receivable allowance $ 4,955 $ 15,230 $ (14,395 ) $ 5,790 (1) Represents charges associated primarily to accruals for early payment discounts, volume discounts and contract rebates recorded as reductions to revenue. Additions to allowance for doubtful accounts are recorded to sales and marketing expenses. (2) The deductions represent actual charges against the accrual described above.

Company Operations and Summar21

Company Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Consolidation	Consolidation— The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Cash and Cash Equivalents	Cash and Cash Equivalents— The Company considers cash equivalents to be highly liquid investments with a maturity at the date of purchase of three months or less.
Accounts Receivable	Accounts Receivable— The Company sells its products directly to hospitals and reference laboratories in the U.S. as well as to distributors in the U.S. and internationally (see Note 7). The Company periodically assesses the financial strength of these customers and establishes reserves for anticipated losses when necessary, which historically have not been material. The Company’s reserves primarily consist of amounts related to cash discounts, volume discounts and contract rebates. The balance of accounts receivable is net of reserves of $7.5 million and $8.2 million at December 31, 2015 and 2014 , respectively.
Concentration of Credit Risk	Concentration of Credit Risk— Financial instruments that potentially subject the Company to significant concentrations of credit risk consists principally of trade accounts receivable. The Company invests its cash equivalents primarily in money market funds. Cash equivalents are maintained with high quality institutions. The Company’s trade accounts receivable are primarily derived from sales to medical distributors, hospitals and reference laboratories in the U.S. (see Note 7). The Company performs credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary, but generally requires no collateral. Credit quality is monitored by evaluation of collection history. The Company believes that the concentration of credit risk in its trade accounts receivables is moderated by its credit evaluation process, relatively short collection terms, the high level of credit worthiness of its customers, and letters of credit issued on the Company’s behalf. Potential credit losses are limited to the gross value of accounts receivable.
Inventories	Inventories— Inventories are stated at the lower of cost (first-in, first-out method) or market. The Company reviews the components of its inventory on a quarterly basis for excess, obsolete and impaired inventory and makes appropriate dispositions as obsolete stock is identified.
Property, Plant and Equipment	Property, Plant and Equipment— Property, plant and equipment is recorded at cost and depreciated over the estimated useful lives of the assets ( three to 15 years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the estimated useful lives of the assets. The total expense for depreciation of fixed assets and amortization of leasehold improvements was $12.7 million , $10.3 million and $7.9 million for the years ended December 31, 2015 , 2014 and 2013 , respectively. Maintenance and minor repairs are charged to operations as incurred.
Intangible Assets	The Company completed its annual evaluation for impairment of goodwill and determined that no impairment of goodwill existed as of December 31, 2015 . Goodwill and Intangible Assets— Intangible assets are recorded at cost and amortized on a straight-line basis over their estimated useful lives, except for software development costs and indefinite-lived intangibles such as goodwill and in-process research and development. Software development costs associated with software to be sold, leased or otherwise marketed are expensed as incurred until technological feasibility has been established. After technological feasibility is established, software development costs are capitalized. The capitalized cost is amortized on a straight-line basis over the estimated product life or on the ratio of current revenues to total projected product revenues, whichever is greater.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets— The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the total book value of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and the eventual disposition are less than its carrying amount. An impairment loss is equal to the excess of the book value of an asset over its determined fair value.
Convertible Debt	Convertible Debt— The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including combination settlement of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in shares of common stock and/or cash) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determines the carrying amount of the liability component by measuring the fair value of similar debt instruments that do not have the conversion feature. If no similar debt instrument exists, the Company estimates fair value by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. Determining the fair value of the debt component requires the use of accounting estimates and assumptions. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense. See Note 2 for additional discussion of the Convertible Senior Notes issued in December 2014.
Revenue Recognition	Revenue Recognition—
Research and Development Costs	Research and Development Costs— Research and development costs are charged to operations as incurred. In conjunction with certain third party service agreements, the Company is required to make periodic payments based on achievement of certain milestones. The costs related to these research and development services are also charged to operations as incurred.
Collaborative Arrangement	Collaborative Arrangement— In July 2012, the Company entered into a collaborative arrangement with Life Technologies Corporation for the development of molecular assays. ASC Topic 808, Collaborative Arrangements (“ASC Topic 808”), defines a collaborative arrangement as an arrangement where the parties are active participants and have exposure to significant risks. The Company accounted for the joint development and commercialization activities with the third-party as a joint risk sharing collaboration in accordance with ASC Topic 808. Payments to the Company from Life Technologies Corporation totaled $0.4 million in 2014 and $1.4 million in 2013. The Company received no payments in 2015 and does not expect additional payments as the development efforts are complete. The reimbursement represents 50% of project development costs based upon mutually agreed upon project plans for each molecular assay. In connection with the collaboration agreement, the Company also entered into a manufacturing and supply agreement with the same third party. As part of that agreement, and upon commercialization, the Company will manufacture and sell assays to the third party at cost plus 20% . Additionally, the Company will receive 40% of the gross margin for sales from the third party to the end customer. In March 2013, the Company entered into a six year instrument supply agreement (the “March 2013 Agreement”) with Life Technologies Corporation. Pursuant to the March 2013 Agreement, the Company paid $0.8 million for distribution rights to sell Life Technologies Corporation’s QuantStudio™ DX diagnostic laboratory instrument for use in the infectious disease field, along with the assays developed under the collaborative agreement.
Product Shipment Costs	Product Shipment Costs— Product shipment costs are included in sales and marketing expense in the accompanying Consolidated Statements of Operations.
Advertising Costs	Advertising Costs— Advertising costs are expensed as incurred.
Deferred Rent	Deferred Rent— Rent expense is recorded on a straight-line basis over the term of the lease. The difference between rent expense and amounts paid under the lease agreement are recorded as deferred rent.
Income Taxes	Income Taxes— Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company’s policy is to recognize the interest expense and penalties related to income tax matters as a component of income tax expense.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The Company uses the fair value hierarchy established in ASC Topic 820 , Fair Value Measurements and Disclosures, that requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts of the Company’s financial instruments, including cash, receivables, accounts payable, and accrued liabilities approximate their fair values due to their short-term nature.
Product Warranty	Product Warranty —The Company generally sells products with a limited product warranty and certain limited indemnifications. Due to product testing, the short time between product shipment and the detection and correction of product failures and a low historical rate of payments on indemnification claims, the historical activity and the related expense were not significant for the fiscal years presented.
Stock-Based Compensation	Stock-Based Compensation —Compensation expense related to stock options granted is recognized ratably over the service vesting period for the entire option. The total number of stock options expected to vest is adjusted by estimated forfeiture rates. The Company determined the estimated fair value of each stock option on the date of grant using the Black-Scholes option valuation model. Compensation expense for restricted stock units (RSUs) is measured at the grant date and recognized ratably over the vesting period. The fair value of RSUs is determined based on the closing market price of the Company’s common stock on the grant date.
Earnings Per Share	Computation of (Loss) Earnings Per Share —For the twelve months ended December 31, 2015 and 2014 , basic loss per share was computed by dividing net loss by the weighted-average number of common shares outstanding, including restricted stock units vested during the period. Diluted earnings per share (“EPS”) reflects the potential dilution that could occur if the earnings were divided by the weighted-average number of common shares and potentially dilutive common shares from outstanding stock options as well as unvested restricted stock units. Potential dilutive common shares were calculated using the treasury stock method and represent incremental shares issuable upon exercise of the Company’s outstanding stock options and unvested restricted stock units. For the twelve months ended December 31, 2015 and 2014 , there were no differences between the number of common shares used for the basic and diluted EPS computation because the Company incurred a net loss and the effect would be anti-dilutive. Stock options and shares of restricted stock that would have been included in the diluted EPS calculation if the Company had earnings amounted to 1.0 million and 1.1 million for the twelve months ended December 31, 2015 and 2014 , respectively. Additionally, stock options are excluded from the calculation of diluted EPS when the combined exercise price, unrecognized stock-based compensation and expected tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive. Stock options totaling 1.9 million and 1.0 million for the twelve months ended December 31, 2015 and 2014 , respectively, were not included in the computation of diluted EPS because the exercise of such options would be anti-dilutive. As discussed in Note 2, the Company issued Convertible Senior Notes (“Convertible Senior Notes”) in December 2014. It is the Company’s intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the “principal portion” and delivery of the “share amount” in excess of the conversion value over the principal portion in cash or shares of common stock (“conversion premium”). No conversion premium existed as of December 31, 2015 and 2014 , therefore, there was no dilutive impact from the Convertible Senior Notes to diluted EPS. For the twelve months ended December 31, 2013 , diluted net income per share was reported based on the more dilutive of the treasury stock or the two-class method. Under the two-class method, net income is allocated to common stock and participating securities. For the twelve months ended December 31, 2013 , the Company’s unvested restricted stock awards and certain unvested restricted stock units met the definition of participating securities. Basic net income per share under the two-class method was computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income per share under the two-class method was computed by dividing net income adjusted for earnings allocated to unvested stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. The Company excludes stock options from the calculation of diluted net income per share when the combined exercise price, unrecognized stock-based compensation and expected tax benefits upon exercise are greater than the average market price for the Company’s common stock because their effect is anti-dilutive.
Comprehensive (Loss) Income	Comprehensive (Loss) Income —Comprehensive (loss) income includes unrealized gains and losses excluded from the Company’s Consolidated Statements of Operations.
Facility Restructuring	Facility Restructuring — In 2013, the Company announced a plan to move its manufacturing operations in Santa Clara, California to Athens, Ohio. Termination benefits for those employees who choose not to relocate are accounted for in accordance with ASC Topic 712, Compensation – Nonretirement Postemployment Benefits , and are recorded when it is probable that employees will be entitled to benefits and the amounts can be reasonably estimated. Estimates of termination benefits are based on the frequency of past termination benefits and the similarity of benefits under the current plan and prior plans. Facility related costs are accounted for in accordance with ASC Topic 420, Exit or Disposal Cost Obligations , and are recorded when the liability is incurred.
Use of Estimates	Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Periods	Accounting Periods —Each of the Company’s fiscal quarters end on the Sunday closest to the end of the calendar quarter. The Company’s fiscal year ends are January 3, 2016, December 28, 2014 and December 29, 2013. For ease of reference, the calendar quarter end dates are used herein.
Recent Accounting Pronouncements	Recent Accounting Pronouncements —In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance codified in Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , which amends the guidance in former ASC 605, Revenue Recognition . This guidance is intended to improve and converge with international standards relating to the financial reporting requirements for revenue from contracts with customers. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current authoritative guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The original guidance was effective for annual reporting periods beginning after December 15, 2016. However, in July 2015, the FASB deferred by one year the effective dates of the new revenue recognition standard for entities reporting under GAAP. As a result, the standard will be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. The Company is currently evaluating the impact of this guidance and expects to adopt the standard in the first quarter of 2018. In August 2014, the FASB issued guidance codified in ASU 2014-15 (Subtopic 205-40), Presentation of Financial Statements - Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . The guidance requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). Management will be required to make this evaluation for both annual and interim reporting periods and will make certain disclosures if it concludes that substantial doubt exists or when its plans alleviate substantial doubt about the entity’s ability to continue as a going concern. Substantial doubt exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). The term probable is used consistently with its use in ASC Topic 450, Contingencies . The guidance is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter 2017, with early adoption permitted. The Company does not expect this guidance to have a significant impact on the consolidated financial statements and expects to adopt the standard for the annual reporting period ended December 31, 2016. In February 2015, the FASB issued guidance codified in ASU 2015-02 (Topic 810), Consolidation - Amendments to the Consolidation Analysis . The guidance affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. Specifically, the guidance amends (i) the identification of variable interests (fees paid to a decision maker or service provider), (ii) the Variable Interest Entity (VIE) characteristics for a limited partnership or similar entity and (iii) the primary beneficiary determination. The guidance is effective for annual periods beginning after December 15, 2015 and for interim reporting periods starting in the first quarter 2016. The Company does not expect this guidance to have a significant impact on the consolidated financial statements and expects to adopt the standard in the first quarter of 2016. In July 2015, the FASB issued guidance codified in ASU 2015-11 (Topic 330), Simplifying the Measurement of Inventory . The guidance applies to inventory that is measured using first-in, first-out (“FIFO”) or average cost. Under the guidance, an entity should measure inventory that is within scope at the lower of cost and net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted as of the beginning of an interim or annual reporting period. The Company does not expect this guidance to have a significant impact on the consolidated financial statements and expects to early adopt the standard in the first quarter of 2016. In November 2015, the FASB issued guidance codified in ASU 2015-17 (Topic 740), Balance Sheet Classification of Deferred Taxes. The guidance requires entities to classify all deferred tax assets and liabilities as non-current on the balance sheet instead of separating deferred taxes into current and non-current amounts. Additionally, entities will no longer allocate valuation allowances between current and non-current deferred tax assets because those allowances will also be classified as non-current. Under current GAAP, in a classified statement of financial position, deferred tax assets and liabilities are separated into a current amount and a non-current amount on the basis of the classification of the related asset or liability for financial reporting. Deferred tax assets and liabilities that are not related to an asset or liability for financial reporting are classified according to the expected reversal date of the temporary difference. The new guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company has elected to early adopt ASU 2015-17 and has presented all deferred tax assets and liabilities as non-current as of December 31, 2015. The Company has applied the standard on a prospective basis. Therefore, the classification of deferred tax assets and liabilities prior to December 31, 2015 have not been changed from the original presentation.
Fair Value Measurements and Disclosures	In conjunction with Financial Accounting Standards Board Accounting Standard Update No. 2009-05, Fair Value Measurements and Disclosures (Topic 820), the Company assigned $28.8 million to the licensed technology and $0.7 million as a one-time charge to cost of sales to settle royalty claims. In determining the fair value allocation between the intangible asset licensed technology and the one-time charge to cost of sales, the Company assessed the past and estimated future revenue streams related to present and future products that use the patents that were subject to the Amendment. The effective life and related amortization of the licensed technology was based on the higher of the percentage of usage or the straight-line method. This percentage of usage was determined using the revenues generated from products covered by the patents that were subject to the Amendment. The terms of the Amendment provide for an estimated useful life of 3.5 years for this asset.

Company Operations and Summar22

Company Operations and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Inventories	Inventories consisted of the following, net of reserves of $0.7 million and $2.2 million at December 31, 2015 and 2014 , respectively (in thousands): December 31, 2015 2014 Raw materials $ 10,289 $ 10,472 Work-in-process (materials, labor and overhead) 7,441 6,834 Finished goods (materials, labor and overhead) 8,658 7,457 Total inventories $ 26,388 $ 24,763
Property, Plant and Equipment	Property, plant and equipment consisted of the following (in thousands): December 31, 2015 2014 Equipment, furniture and fixtures $ 59,736 $ 64,233 Building and improvements 33,048 32,074 Leased instruments 18,280 12,395 Land 1,080 1,080 Total property, plant and equipment, gross 112,144 109,782 Less: accumulated depreciation and amortization (59,597 ) (60,556 ) Total property, plant and equipment, net $ 52,547 $ 49,226
Summary of Intangible Assets	Goodwill and intangible assets consisted of the following (dollar amounts in thousands): December 31, 2015 December 31, 2014 Description Weighted-average useful life (years) Gross assets Accumulated amortization Net Gross assets Accumulated amortization Net Goodwill Indefinite $ 84,179 $ (3,449 ) $ 80,730 $ 84,197 $ (3,449 ) $ 80,748 Purchased technology 8.4 52,560 (34,911 ) 17,649 51,870 (28,570 ) 23,300 Customer relationships 7.6 7,171 (4,972 ) 2,199 7,214 (3,978 ) 3,236 In-process research and development Indefinite — — — 690 — 690 License agreements 10.6 5,512 (2,542 ) 2,970 34,324 (30,050 ) 4,274 Patent and trademark costs 12.3 10,530 (2,588 ) 7,942 10,530 (1,725 ) 8,805 Software development costs 5 2,913 (1,840 ) 1,073 2,849 (1,264 ) 1,585 Total goodwill and intangible assets $ 162,865 $ (50,302 ) $ 112,563 $ 191,674 $ (69,036 ) $ 122,638
Summary of Expected Future Annual Amortization Expense	The expected future annual amortization expense of the Company’s intangible assets is as follows (in thousands): For the years ending December 31, Amortization expense 2016 $ 9,288 2017 9,000 2018 3,430 2019 2,175 2020 1,796 Thereafter 6,144 Total $ 31,833
Schedule of Other Current Liabilities	Other current liabilities— Other current liabilities consisted of the following (in thousands): December 31, 2015 2014 Customer incentives $ 4,030 $ 4,729 Accrued research and development costs 773 990 Other 2,196 2,324 Total other current liabilities $ 6,999 $ 8,043
Basic and Diluted EPS	The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2013 (in thousands, except per share amounts): 2013 Basic net income per share: Net income $ 7,390 Less: income allocated to participating securities (17 ) Net income allocated to common stockholders $ 7,373 Weighted average common shares outstanding — basic 33,836 Net income per share — basic $ 0.22 Diluted net income per share: Net income $ 7,390 Less: income allocated to participating securities (16 ) Net income allocated to common stockholders $ 7,374 Weighted average common shares outstanding — basic 33,836 Dilutive securities 1,111 Weighted average common shares outstanding — diluted 34,947 Net income per share — diluted $ 0.21
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	The following table presents the effect of the retrospective application of this change in accounting principle on the Company’s Consolidated Balance Sheets as of December 31, 2014: Consolidated Balance Sheets (in thousands) As Reported December 31, 2014 Effect of Change in Accounting Principle After change in Accounting Principle ASSETS Current assets: Prepaid expenses and other current assets $ 3,554 $ (640 ) $ 2,914 Total current assets 275,121 (640 ) 274,481 Other non-current assets 4,565 (3,499 ) 1,066 Total assets $ 451,550 $ (4,139 ) $ 447,411 LIABILITIES AND STOCKHOLDERS’ EQUITY Long-term debt 142,097 (4,139 ) 137,958 Total liabilities and stockholders’ equity $ 451,550 $ (4,139 ) $ 447,411

Debt Tables (Tables)

Debt Tables (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The following table summarizes information about the equity and liability components of the Convertible Senior Notes (dollars in thousands). The fair values of the respective notes outstanding were measured based on quoted market prices. December 31, 2015 2014 Principal amount of Convertible Senior Notes outstanding $ 172,500 $ 172,500 Unamortized discount of liability component (25,703 ) (30,403 ) Unamortized deferred issuance costs (1) (3,500 ) (4,139 ) Net carrying amount of liability component 143,297 137,958 Less: current portion — — Long-term debt $ 143,297 $ 137,958 Carrying value of equity component, net of issuance costs $ 29,758 $ 29,758 Fair value of outstanding Convertible Senior Notes (2) $ 170,120 $ 190,613 Remaining amortization period of discount on the liability component 5 years 6 years

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Components of (Benefit) Provision for Income Taxes	Significant components of the (benefit) provision for income taxes are as follows (in thousands): December 31, 2015 2014 2013 Current: Federal $ 948 $ 61 $ (565 ) State 399 (1,294 ) 810 Foreign 41 69 18 Total current provision (benefit) 1,388 (1,164 ) 263 Deferred: Federal (4,624 ) (5,267 ) (2,584 ) State — 2,488 (1,635 ) Foreign 18 34 — Total deferred benefit (4,606 ) (2,745 ) (4,219 ) Benefit for income taxes $ (3,218 ) $ (3,909 ) $ (3,956 )
Schedule of Income before (Benefit) Provision for Income Taxes	The Company’s (loss) income before (benefit) provision for income taxes was subject to taxes in the following jurisdictions for the following periods (in thousands): December 31, 2015 2014 2013 United States $ (9,480 ) $ (11,328 ) $ 3,364 Foreign 183 345 70 (Loss) income before benefit for income taxes $ (9,297 ) $ (10,983 ) $ 3,434
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets as of December 31, 2015 and 2014 are shown below (in thousands). December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ 1,199 $ 2,236 Intangible assets 3,574 3,366 Sale-leaseback, net 1,224 1,424 Allowance for returns and discounts 4,308 4,574 Stock based compensation 9,884 8,255 Tax credit carryforwards 2,341 2,060 Other, net 5,200 4,472 Total deferred tax assets 27,730 26,387 Valuation allowance for deferred tax assets (3,087 ) (2,331 ) Total deferred tax assets, net of valuation allowance 24,643 24,056 Deferred tax liabilities: Convertible Senior Notes (9,474 ) (11,267 ) Intangible assets (9,977 ) (12,939 ) Property, plant and equipment (7,162 ) (6,424 ) Total deferred tax liabilities (26,613 ) (30,630 ) Net deferred tax assets and liabilities $ (1,970 ) $ (6,574 )
Reconciliation of Income Tax Computed at Federal Statutory Rate	Year ended December 31, 2015 2014 2013 Tax (benefit) expense at statutory tax rate (3,254 ) (3,844 ) 1,214 State (benefit) taxes, net of federal tax (benefit) (235 ) (151 ) 63 Permanent differences 157 70 (76 ) Federal and state research credits—current year (722 ) (765 ) (1,046 ) Federal research credits - prior year — — (527 ) (Release) accrual of uncertain tax positions 101 (21 ) 369 Expiration of statutes for uncertain tax positions — (953 ) (3,452 ) Impact of change in federal and state tax rate on revaluing deferred tax assets 56 110 (581 ) Change in valuation allowance 756 2,331 — Acquisition related adjustments — (485 ) — Other (77 ) (201 ) 80 Benefit for income taxes (3,218 ) (3,909 ) (3,956 )
Summary of Unrecognized Tax Benefits	The following table summarizes the activity related to the Company’s for unrecognized tax benefits (in thousands): Year ended December 31, 2015 2014 2013 Beginning balance $ 7,065 $ 7,765 $ 9,051 (Decreases) increases related to prior year tax positions (12 ) (68 ) 773 Increases related to current year tax positions 631 642 1,019 Decreases due to settlements — (42 ) — Expiration of the statute of limitations for the assessment of taxes — (1,232 ) (3,078 ) Ending balance $ 7,684 $ 7,065 $ 7,765

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation Expense Related to Stock-Based Compensation Plans	tock-based compensation expense related to stock options, RSUs and PSUs was as follows (in thousands): Year ended December 31, 2015 2014 2013 Cost of sales $ 581 $ 609 $ 815 Research and development 734 1,062 1,912 Sales and marketing 1,554 1,059 821 General and administrative 4,550 3,994 5,223 $ 7,419 $ 6,724 $ 8,771
Estimated Fair Value of Each Stock Option Award	The estimated fair value of each stock option was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions for the option grants: Year ended December 31, 2015 2014 2013 Risk-free interest rate 1.50 % 1.59 % 0.86 % Expected option life (in years) 6.24 5.78 5.53 Volatility rate 40 % 42 % 44 % Dividend rate — % — % — %
Summary of Status of Stock Option Activity	A summary of the status of stock option activity for the years ended December 31, 2013 , 2014 and 2015 is as follows (in thousands, except price data and years): Number of Shares Weighted- average exercise price per share Weighted- average remaining contractual term (in years) Aggregate intrinsic value Outstanding at January 1, 2013 3,600 $ 13.15 Granted 529 22.36 Exercised (642 ) 12.16 Cancelled (13 ) 10.61 Outstanding at December 31, 2013 3,474 14.74 Granted 559 26.63 Exercised (251 ) 13.67 Cancelled (175 ) 20.63 Outstanding at December 31, 2014 3,607 16.37 Granted 659 23.15 Exercised (168 ) 12.30 Cancelled (131 ) 23.41 Outstanding at December 31, 2015 3,967 $ 17.44 5.54 $ 19,225 Vested and expected to vest at December 31, 2015 3,827 $ 17.20 5.52 $ 19,192 Exercisable at December 31, 2015 2,657 $ 14.37 4.16 $ 18,503 Available for future grant at December 31, 2015 1,434
Summary of Status of Stock Awards Activity	A summary of the status of stock awards activity for the years ended December 31, 2013 , 2014 and 2015 is as follows (in thousands, except price data): Shares Weighted-average grant date fair value Non-vested at January 1, 2013 522 $ 13.87 Granted 74 23.53 Vested (141 ) 23.43 Forfeited (1 ) 15.26 Non-vested at December 31, 2013 454 16.22 Granted 145 25.73 Vested (174 ) 28.27 Forfeited (23 ) 18.19 Non-vested at December 31, 2014 402 14.84 Granted 171 22.79 Vested (96 ) 18.01 Forfeited (18 ) 22.87 Non-vested at December 31, 2015 459 $ 21.61

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments for Minimum Rentals under Non-cancelable Leases	The Company leases its facilities and certain equipment. Commitments for minimum rentals under non-cancelable leases at the end of 2015 are as follows (in thousands): Years ending December 31, Operating Leases Lease obligation 2016 $ 2,383 $ 922 2017 1,885 931 2018 1,644 940 2019 1,669 950 2020 1,684 959 Thereafter 1,971 1,079 Total minimum lease payments $ 11,236 5,781 Less: amount representing interest (1,164 ) Present value of lease obligation 4,617 Less: current portion (585 ) Long-term lease obligation $ 4,032

Industry and Geographic Infor27

Industry and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Reporting [Abstract]
Sales to Individual Customers in Excess of 10% of Total Revenue	The Company had sales to individual customers in excess of 10% of total revenue, as follows: Year ended December 31, 2015 2014 2013 Customer: A 20 % 19 % 19 % B 17 % 18 % 16 % C 11 % 11 % 8 % 48 % 48 % 43 %
Long-Lived Assets (Excluding Intangible Assets) and Total Net Revenue	The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands): Long-lived assets as of December 31, Total revenue year ended December 31, 2015 2014 2015 2014 2013 Domestic $ 52,426 $ 49,052 $ 168,809 $ 159,845 $ 154,626 Foreign 121 174 27,320 24,313 22,699 $ 52,547 $ 49,226 $ 196,129 $ 184,158 $ 177,325
Consolidated Net Product Revenues by Disease State	Consolidated net product revenues by disease state are as follows (in thousands): Year ended December 31, 2015 2014 2013 Infectious disease $ 141,857 $ 130,416 $ 128,079 Women’s health 37,161 34,332 33,328 Gastrointestinal disease 7,224 7,414 6,622 Royalty, license fees and grant revenue 6,189 7,681 3,917 Other 3,698 4,315 5,379 $ 196,129 $ 184,158 $ 177,325

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s hierarchy for its assets and liabilities measured at fair value on a recurring basis as of the following periods (in thousands): December 31, 2015 December 31, 2014 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Cash equivalents 133,147 — — 133,147 3,057 — — 3,057 Total assets measured at fair value $ 133,147 $ — $ — $ 133,147 $ 3,057 $ — $ — $ 3,057 Liabilities: Contingent consideration — — 5,516 5,516 — — 5,756 5,756 Total liabilities measured at fair value $ — $ — $ 5,516 $ 5,516 $ — $ — $ 5,756 $ 5,756
Changes in Estimated Fair Value of Contingent Consideration Liabilities	Changes in estimated fair value of contingent consideration liabilities from December 31, 2014 through December 31, 2015 are as follows (in thousands): Contingent consideration liability (Level 3 measurement) Balance at December 31, 2014 $ 5,756 Cash payments (129 ) Net gain recorded for fair value adjustments (88 ) Unrealized gain on foreign currency translation (23 ) Balance at December 31, 2015 $ 5,516

Selected Quarterly Financial 29

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2015 Total revenues (1) $ 61,701 $ 35,204 $ 46,812 $ 52,412 Cost of sales (excludes amortization of intangible assets) 21,112 15,493 16,961 18,122 Gross profit (2) 39,018 18,121 28,261 32,700 Total costs and expenses (1) 53,012 45,029 45,600 49,750 Net (loss) income 3,991 (8,931 ) (762 ) (377 ) Basic net (loss) earnings per share (3) 0.12 (0.26 ) (0.02 ) (0.01 ) Diluted net (loss) earnings per share (3) 0.11 (0.26 ) (0.02 ) (0.01 ) 2014 Total revenues (1) $ 47,129 $ 31,883 $ 41,193 $ 63,953 Cost of sales (excludes amortization of intangible assets) 20,247 15,902 16,768 21,263 Gross profit (2) 25,311 14,410 22,854 41,120 Total costs and expenses (1) 49,146 41,868 51,314 51,038 Net income (loss) (1,512 ) (6,908 ) (5,767 ) 7,113 Basic net earnings (loss) per share (3) (0.04 ) (0.20 ) (0.17 ) 0.21 Diluted net earnings (loss) per share (3) (0.04 ) (0.20 ) (0.17 ) 0.20 First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) 2015 Total revenues (1) $ 61,701 $ 35,204 $ 46,812 $ 52,412 Cost of sales (excludes amortization of intangible assets) 21,112 15,493 16,961 18,122 Gross profit (2) 39,018 18,121 28,261 32,700 Total costs and expenses (1) 53,012 45,029 45,600 49,750 Net (loss) income 3,991 (8,931 ) (762 ) (377 ) Basic net (loss) earnings per share (3) 0.12 (0.26 ) (0.02 ) (0.01 ) Diluted net (loss) earnings per share (3) 0.11 (0.26 ) (0.02 ) (0.01 ) 2014 Total revenues (1) $ 47,129 $ 31,883 $ 41,193 $ 63,953 Cost of sales (excludes amortization of intangible assets) 20,247 15,902 16,768 21,263 Gross profit (2) 25,311 14,410 22,854 41,120 Total costs and expenses (1) 49,146 41,868 51,314 51,038 Net income (loss) (1,512 ) (6,908 ) (5,767 ) 7,113 Basic net earnings (loss) per share (3) (0.04 ) (0.20 ) (0.17 ) 0.21 Diluted net earnings (loss) per share (3) (0.04 ) (0.20 ) (0.17 ) 0.20 (1) Includes reclassification of freight billed to customers from sales and marketing expense to revenue of $0.4 million and $0.3 million for the first and second quarters of 2015, respectively, and $0.5 million , $0.4 million , $0.3 million , and $0.4 million for the first, second, third, and fourth quarters of 2014, respectively. (2) Included in 2015 and 2014 quarterly gross profit is amortization of intangible assets of $1.6 million , $1.6 million , $1.6 million and $1.5 million for the first quarter, second quarter, third quarter and fourth quarter, respectively. (3) Basic and diluted EPS amounts in each quarter are computed using the weighted-average number of shares outstanding during that quarter, while basic and diluted EPS for the full year is computed using the weighted-average number of shares outstanding during the year. Therefore, the sum of the four quarters’ basic or diluted EPS may not equal the full year basic or diluted EPS.

Company Operations and Summar30

Company Operations and Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands, shares in Millions	Sep. 10, 2014USD ($)	Nov. 06, 2012USD ($)	Apr. 30, 2015USD ($)	Mar. 31, 2013USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)Segmentshares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)	Sep. 30, 2015USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Number of business segment | Segment						1
Cash and cash equivalents maximum maturity period						3 months
Product shipment costs					$ 4,100	$ 3,900	$ 3,800
Excluded from Computation of Earnings Per Share, Amount | shares						1	1.1
Liabilities and Equity						$ 406,505	$ 447,411
Account receivable, reserves						7,500	8,200
Advertising cost expensed					700	$ 700	400
Revenue Recognition Milestone Method Payment Received	$ 10,600		$ 2,400				2,500
Percentage cost plus sale assays to third party						20.00%
Maximum Amount Of Milestone Based Grant Related To Research And Commercialization Activities	$ 12,600	$ 8,300
Prepaid expenses and other current assets						$ 4,344	2,914
Amortization expense						10,200	17,400	$ 16,600
Net of reserves, inventories						700	2,200
Depreciation and Amortization						12,700	10,300	7,900
Impairment loss						0	3,558	0
Fund received for research and development activities		$ 2,600
Unbilled Change Orders, Amount Expected to be Collected after One Year									$ 2,800
Company's grant revenue						5,100	6,300	2,600
Restricted cash						63	3,127
Deferred grant revenue						3,658	6,330
Reimbursement Related To Research And Development Expense						$ 0	400	1,400
Reimbursement percentage upon project development cost						50.00%
Interest in gross margin for sales from third party to end customer						40.00%
Finite-Lived Intangible Asset, Useful Life						3 years 6 months
Restructuring costs and asset impairment charges						$ 0	1,800
Prior period reclassification adjustment							1,500	1,900
2,015						9,288
Assets, Current						240,664	274,481
Other non-current assets						731	1,066
Assets						406,505	447,411
Long-term Debt						$ 143,297	137,958
Other Noncurrent Liabilities [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Prior period reclassification adjustment							700
Software development costs [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life						5 years
Capitalized Software Costs [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense						$ 600	600	300
Distribution rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Period of instrument supply agreement with Life Technologies Corporation				6 years
Acquisition of distribution rights				$ 800
License agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense					$ 8,000	$ 700	8,000
Finite-Lived Intangible Asset, Useful Life						10 years 7 months
License agreements [Member] | Cost of sales [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense						$ 700	8,000	$ 8,000
Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of the assets						3 years
Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of the assets						15 years
Software and Software Development Costs [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Impairment loss							1,500
Scenario, Previously Reported [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Liabilities and Equity							451,550
Prepaid expenses and other current assets							3,554
Assets, Current							275,121
Other non-current assets							4,565
Assets							451,550
Long-term Debt							142,097
New Accounting Pronouncement, Early Adoption, Effect [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Liabilities and Equity							(4,139)
Prepaid expenses and other current assets							(640)
Assets, Current							(640)
Other non-current assets							(3,499)
Assets							(4,139)
Long-term Debt							$ (4,139)

Company Operations and Summar31

Company Operations and Summary of Significant Accounting Policies - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 10,289	$ 10,472
Work-in-process (materials, labor and overhead)	7,441	6,834
Finished goods (materials, labor and overhead)	8,658	7,457
Total inventories	$ 26,388	$ 24,763

Company Operations and Summar32

Company Operations and Summary of Significant Accounting Policies - Property, Plant and equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 112,144	$ 109,782
Less: accumulated depreciation and amortization	(59,597)	(60,556)
Total property, plant and equipment, net	52,547	49,226
Equipment, furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	59,736	64,233
Building and building improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	33,048	32,074
Instruments available for lease [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	18,280	12,395
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,080	$ 1,080

Company Operations and Summar33

Company Operations and Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Goodwill And Intangible Assets [Line Items]
Goodwill Gross	$ 84,179	$ 84,197
Accumulated Amortization on Goodwill	(3,449)	(3,449)
Goodwill Net	$ 80,730	80,748
Weighted-Average Useful Life (years)	3 years 6 months
Accumulated Amortization	$ (50,302)	(69,036)
Total	31,833
Gross intangible asset including Goodwill	162,865	191,674
Net intangible asset including Goodwill	112,563	122,638
In Process Research and Development [Member]
Goodwill And Intangible Assets [Line Items]
Accumulated Amortization	0	0
Gross Assets	0	690
Net	$ 0	690
Purchased technology [Member]
Goodwill And Intangible Assets [Line Items]
Weighted-Average Useful Life (years)	8 years 4 months 24 days
Gross Assets	$ 52,560	51,870
Accumulated Amortization	(34,911)	(28,570)
Total	$ 17,649	23,300
Customer relationships [Member]
Goodwill And Intangible Assets [Line Items]
Weighted-Average Useful Life (years)	7 years 6 months 30 days
Gross Assets	$ 7,171	7,214
Accumulated Amortization	(4,972)	(3,978)
Total	$ 2,199	3,236
License agreements [Member]
Goodwill And Intangible Assets [Line Items]
Weighted-Average Useful Life (years)	10 years 7 months
Gross Assets	$ 5,512	34,324
Accumulated Amortization	(2,542)	(30,050)
Total	$ 2,970	4,274
Patent and trademark costs [Member]
Goodwill And Intangible Assets [Line Items]
Weighted-Average Useful Life (years)	12 years 4 months
Gross Assets	$ 10,530	10,530
Accumulated Amortization	(2,588)	(1,725)
Total	$ 7,942	8,805
Software development costs [Member]
Goodwill And Intangible Assets [Line Items]
Weighted-Average Useful Life (years)	5 years
Gross Assets	$ 2,913	2,849
Accumulated Amortization	(1,840)	(1,264)
Total	$ 1,073	$ 1,585

Company Operations and Summar34

Company Operations and Summary of Significant Accounting Policies - Summary of Expected Future Annual Amortization Expense (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2,015	$ 9,288
2,016	9,000
2,017	3,430
2,018	2,175
2,019	1,796
Thereafter	6,144
Total	$ 31,833

Company Operations and Summar35

Company Operations and Summary of Significant Accounting Policies - Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Customer incentives	$ 4,030	$ 4,729
Accrued research and development costs	773	990
Other	2,196	2,324
Total other current liabilities	$ 6,999	$ 8,043

Company Operations and Summar36

Company Operations and Summary of Significant Accounting Policies - Basic and Diluted EPS (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Excluded from Computation of Earnings Per Share, Amount									1,000	1,100
Basic net income per share:
Net income	$ (377)	$ (762)	$ (8,931)	$ 3,991	$ 7,113	$ (5,767)	$ (6,908)	$ (1,512)	$ (6,079)	$ (7,074)	$ 7,390
Less: income allocated to participating securities											(17)
Net income allocated to common stockholders											$ 7,373
Weighted average common shares outstanding — basic									34,104	34,451	33,836
Net income per share — basic	$ (0.01)	$ (0.02)	$ (0.26)	$ 0.12	$ 0.21	$ (0.17)	$ (0.20)	$ (0.04)	$ (0.18)	$ (0.21)	$ 0.22
Diluted net income per share:
Net income	$ (377)	$ (762)	$ (8,931)	$ 3,991	$ 7,113	$ (5,767)	$ (6,908)	$ (1,512)	$ (6,079)	$ (7,074)	$ 7,390
Less: income allocated to participating securities											(16)
Net income allocated to common stockholders											$ 7,374
Weighted average common shares outstanding — basic									34,104	34,451	33,836
Dilutive securities											1,111
Weighted average common shares outstanding — diluted									34,104	34,451	34,947
Net income per share — diluted	$ (0.01)	$ (0.02)	$ (0.26)	$ 0.11	$ 0.20	$ (0.17)	$ (0.20)	$ (0.04)	$ (0.18)	$ (0.21)	$ 0.21
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									1,900	1,000	500

Debt Convertible Senior Notes (

Debt Convertible Senior Notes (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)d	Dec. 31, 2014USD ($)$ / shares	Dec. 31, 2013USD ($)	Dec. 08, 2014USD ($)
Debt Instrument [Line Items]
Interest expense, Convertible Senior Notes, Amortization		$ 300
Interest Expense, Debt	$ 10,900	600
Proceeds from issuance of Convertible Senior Notes	0	172,500	$ 0
Fair value of outstanding Convertible Senior Notes (2)		190,600
Other Current Assets [Member]
Debt Instrument [Line Items]
Deferred financing costs		300
Other non-current assets [Member]
Debt Instrument [Line Items]
Deferred financing costs		200	$ 500
3.25% Convertible Senior Notes due 2020 [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Principal amount of Convertible Senior Notes outstanding	172,500	172,500
Convertible Senior Notes, face amount		$ 172,500		$ 172,500
Convertible Senior Notes, interest rate, stated percentage		3.25%
Debt issuance cost	$ 5,100
Deferred financing costs		$ 4,200
Remaining amortization period of discount on the liability component	5 years	6 years
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 900
Debt Instrument, Unamortized Discount	$ 25,703	$ 30,403
Convertible Senior Notes, conversion ratio	31.1891
Convertible Senior Notes, conversion price | $ / shares		$ 32.06
Convertible Senior Notes, threshold trading days | d	20
Convertible Senior Notes, threshold consecutive trading days	30 years
Convertible Senior Notes, threshold percentage of stock price trigger	130.00%
Convertible Senior Notes, threshold consecutive business days	5 years
Debt Instrument, Convertible, Threshold Consecutive Trading Days, Following Consecutive Business Days	5 years
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger, Following Consecutive Business Days	98.00%
Convertible Senior Notes, observation period	25 years
Carrying value of equity component, net of issuance costs	$ 29,758	$ 29,758		30,700
Interest expense, Convertible Senior Notes, Amortization	5,300
Interest expense, Convertible Senior Notes	5,600	300
Convertible Senior Notes, fair value disclosures				$ 141,900
Proceeds from issuance of Convertible Senior Notes	172,500
Fair value of outstanding Convertible Senior Notes (2)	170,120	190,613
3.25% Convertible Senior Notes due 2020 [Member] | Other Current Assets [Member]
Debt Instrument [Line Items]
Deferred financing costs		600
3.25% Convertible Senior Notes due 2020 [Member] | Other Current Assets [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Deferred financing costs	$ 3,500	4,139
3.25% Convertible Senior Notes due 2020 [Member] | Other non-current assets [Member]
Debt Instrument [Line Items]
Deferred financing costs		$ 3,500

Debt Debt schedule (Details)

Debt Debt schedule (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 08, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Long-term debt	$ 143,297	$ 137,958
Fair value of outstanding Convertible Senior Notes (2)		190,600
Convertible Debt [Member] | 3.25% Convertible Senior Notes due 2020 [Member]
Debt Instrument [Line Items]
Principal amount of Convertible Senior Notes outstanding	172,500	172,500
Unamortized deferred issuance costs (1)	(25,703)	(30,403)
Deferred financing costs		(4,200)
Net carrying amount of liability component	143,297	137,958
Less: current portion	0	0
Long-term debt	143,297	137,958
Carrying value of equity component, net of issuance costs	29,758	29,758	$ 30,700
Fair value of outstanding Convertible Senior Notes (2)	$ 170,120	$ 190,613
Remaining amortization period of discount on the liability component	5 years	6 years
Other non-current assets [Member]
Debt Instrument [Line Items]
Deferred financing costs		$ (200)		$ (500)
Other non-current assets [Member] | 3.25% Convertible Senior Notes due 2020 [Member]
Debt Instrument [Line Items]
Deferred financing costs		$ (3,500)

Line of Credit (Detail)

Line of Credit (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Aug. 10, 2012USD ($)
Line of Credit Facility [Line Items]
Line of Credit Facility, Funded Debt	$ 15,000,000
Amount available under the Senior Credit Facility		$ 126,100,000
Amount outstanding under the Senior Credit Facility		0	$ 0
Line of credit facility covenant compliance	As of December 31, 2015 and 2014 , the Company was in compliance with all financial covenants.
Other non-current assets [Member]
Line of Credit Facility [Line Items]
Deferred financing costs		200,000	$ 500,000
Other Current Assets [Member]
Line of Credit Facility [Line Items]
Deferred financing costs		300,000
Senior Credit Facility [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility				$ 140,000,000
Deferred financing costs		$ 1,000,000
Senior Credit Facility, maturity date	Aug. 10, 2017
Senior Credit Facility, adjusted EBITDA ratio	3
Senior Credit Facility, Interest coverage ratio	3
London Interbank Offered Rate (LIBOR) [Member] | Senior Credit Facility [Member]
Line of Credit Facility [Line Items]
Base rate	1.00%
Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Senior Credit Facility [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility, applicable margin		1.25%
Minimum [Member] | Base Rate [Member] | Senior Credit Facility [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility, applicable margin		0.25%
Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member] | Senior Credit Facility [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility, applicable margin		2.50%
Maximum [Member] | Base Rate [Member] | Senior Credit Facility [Member]
Line of Credit Facility [Line Items]
Senior Credit Facility, applicable margin		1.50%

Income Taxes - Components of (B

Income Taxes - Components of (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal		$ 948	$ 61	$ (565)
State		399	(1,294)	810
Foreign		41	69	18
Total current provision (benefit)		1,388	(1,164)	263
Deferred:
Federal		(4,624)	(5,267)	(2,584)
State		0	2,488	(1,635)
Foreign		18	34	0
Total deferred benefit		(4,606)	(2,745)	(4,219)
Benefit for income taxes	$ (3,956)	$ (3,218)	$ (3,909)	$ (3,956)

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income before (Benefit) Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
United States	$ (9,480)	$ (11,328)	$ 3,364
Foreign	183	345	70
(Loss) income before benefit for income taxes	$ (9,297)	$ (10,983)	$ 3,434

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating loss carryforwards	$ 1,199	$ 2,236
Intangible assets	3,574	3,366
Sale-leaseback, net	1,224	1,424
Allowance for returns and discounts	4,308	4,574
Stock based compensation	9,884	8,255
Tax credit carryforwards	2,341	2,060
Other, net	5,200	4,472
Total deferred tax assets	27,730	26,387
Valuation allowance for deferred tax assets	(3,087)	(2,331)
Total deferred tax assets	24,643	24,056
Deferred tax liabilities:
Convertible Senior Notes	(9,474)	(11,267)
Intangible assets	(9,977)	(12,939)
Property, plant and equipment	(7,162)	(6,424)
Deferred Tax Liabilities, Gross	(26,613)	(30,630)
Total deferred tax liabilities	$ (1,970)	$ (6,574)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes Disclosure [Line Items]
Deferred Tax Assets, Valuation Allowance	$ 3,087		$ 3,087	$ 2,331
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			800
Unrecognized Tax Benefits	7,684	$ 7,765	7,684	7,065	$ 7,765	$ 9,051
Deferred tax benefits	1,300		1,300	1,500
Federal Net Operating Loss carryforwards	1,500		1,500
State Net Operating Loss carryforwards	17,600		17,600
Federal alternative minimum tax credit			500
Gross research credits		1,046	722	765
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount		527	0	0
Deferred Tax Liabilities, Undistributed Foreign Earnings	400		$ 400
Cumulative changes in ownership percentage			50.00%
Cumulative changes in ownership period			3 years
Realized upon settlement			50.00%
Unrecognized tax benefits that would impact effective tax rate	5,600		$ 5,600	5,200
Accrued interest and penalties associated with uncertain tax positions	200		200
Interest expense, net of accrued interest reversed		$ (300)	100	(200)
Income tax reserves and related interest				$ 1,000	3,500
Federal research credits [Member]
Income Taxes Disclosure [Line Items]
Federal research credits	2,700		$ 2,700
Federal research credits, expiration date			Dec. 31, 2032
Gross State Research Credits [Member]
Income Taxes Disclosure [Line Items]
Gross research credits			$ 7,900
Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount			7,700
Effective Income Tax Rate Reconciliation, Tax Credit, Investment, Amount			$ 200
Federal [Member]
Income Taxes Disclosure [Line Items]
Gross research credits	$ 400				$ 500

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Computed at Federal Statutory Rate (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Tax (benefit) expense at statutory tax rate	$ 1,214	$ (3,254)	$ (3,844)
State (benefit) taxes, net of federal tax (benefit)	63	(235)	(151)
Permanent differences	(76)	157	70
Federal and state research credits—current year	(1,046)	(722)	(765)
Federal research credits - prior year	(527)	0	0
(Release) accrual of uncertain tax positions	369	101	(21)
Expiration of statutes for uncertain tax positions	(3,452)	0	(953)
Impact of change in federal and state tax rate on revaluing deferred tax assets	(581)	56	110
Change in valuation allowance	0	756	2,331
Acquisition related adjustments	0	0	(485)
Other	80	(77)	(201)
Benefit for income taxes	$ (3,956)	$ (3,218)	$ (3,909)	$ (3,956)

Income Taxes - Summary of Unrec

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning balance		$ 7,065	$ 7,765
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	$ 773	(12)	(68)
Increases related to current year tax positions	1,019	631	642
Decreases due to settlements	0	0	(42)
Expiration of the statute of limitations for the assessment of taxes	(3,078)	0	(1,232)
Unrecognized tax benefits, ending balance	$ 7,765	$ 7,684	$ 7,065

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Dec. 20, 2013	Apr. 23, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 02, 2014	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred Bonus Liability			$ 400	$ 700	$ 400
Preferred stock, shares authorized			5,000,000	5,000,000	5,000,000
Preferred stock, shares outstanding				0	0
Exercisable, Weighted Average Remaining Contractual Term			4 years 1 month 28 days
Restricted stock granted			171,000	145,000	74,000
Additional stock-based compensation expense				$ 300	$ 1,900
Share-based compensation expense recognized			$ 7,419	$ 6,724	$ 8,771
Exercise price of stock			$ 17.44	$ 16.37	$ 14.74		$ 13.15
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			1,434,000
Deferred period of grants (Condition 1)			1 year
Percentage of premium on amount deferred (Condition 1)			10.00%
Deferred period of grants (Condition 2)			2 years
Percentage of premium on amount deferred (Condition 2)			20.00%
Deferred period of grants (Condition 3)			4 years
Percentage of premium on amount deferred (Condition 3)			30.00%
Minimum percentage of common stock under payroll deductions			10.00%
Fair value of payroll deductions			85.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period			6 years
Stock sold under the plan			1,131,493
Capital shares reserved for future issuance			118,507
Payments for repurchase of common stock		$ 50,000	$ 30,934	$ 1,956	$ 2,157
Repurchase of available shares under share repurchase program			1,397,000
Stock Repurchased During Period, Value			$ 30,400	$ 1,956	$ 2,157
Exercise of stock options			168,000	251,000	642,000
Shares reserved for purchase under ESPP			118,507
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercisable, Weighted Average Remaining Contractual Term			10 years
Restricted stock granted			200,000	100,000	100,000
Performance-based vesting period			4 years			3 years
Share-based compensation expense recognized			$ 2,000	$ 2,100	$ 4,000
Employee Deferred Bonus Compensation Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized			$ 700	$ 300	$ 800
2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve under equity incentive plans			5,900,000
2010 Plan [Member] | Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance-based vesting period			1 year
Non-employee director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock granted			500,000	400,000	400,000
Member of Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Repurchase of available shares under share repurchase program	37,709
Exercise of stock options	76,687
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of deferred 2011 cash bonus			50.00%
Minimum [Member] | 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of stock			$ 8.50
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of deferred 2011 cash bonus			100.00%
Maximum [Member] | 2010 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of stock			$ 27.91

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 7,419	$ 6,724	$ 8,771
Weighted-average grant date fair value of stock options granted	$ 9.46	$ 10.96	$ 9.19
Total intrinsic value for options exercised	$ 1,600	$ 2,800	$ 8,100
Total unrecognized compensation expense related to non-vested stock options	$ 6,600
Expected weighted-average period of recognition for unrecognized compensation expense	2 years 2 months
Maximum contractual term	10 years
Deferred Bonus Liability	$ 400	700	400
Deferred bonus compensation program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	700	300	800
Recorded as a component of accrued payroll and related expenses	600	300	700
Restricted stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 2,000	2,100	4,000
Expected weighted-average period of recognition for unrecognized compensation expense	2 years 9 months
Number of restricted share units issued	0.1
Total unrecognized compensation expense related to non-vested stock awards	$ 3,000
Stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense recognized	$ 4,700	$ 4,300	$ 4,000

Stock-Based Compensation - Comp

Stock-Based Compensation - Compensation Expense Related to Stock-Based Compensation Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 7,419	$ 6,724	$ 8,771
Cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	581	609	815
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	734	1,062	1,912
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,554	1,059	821
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,550	$ 3,994	$ 5,223

Stock-Based Compensation - Esti

Stock-Based Compensation - Estimated Fair Value of Each Stock Option Award (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Risk-free interest rate	1.50%	1.59%	0.86%
Expected option life (in years)	6 years 2 months 25 days	5 years 9 months 10 days	5 years 6 months 11 days
Volatility rate	40.00%	42.00%	44.00%
Dividend rate	0.00%	0.00%	0.00%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Status of Stock Option Activity (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 6 months 15 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning Balance, Number of Shares	3,607	3,474	3,600
Granted, Number of Shares	659	559	529
Exercised, Number of Shares	(168)	(251)	(642)
Cancelled, Number of Shares	(131)	(175)	(13)
Ending Balance, Number of Shares	3,967	3,607	3,474
Vested and Expected to Vest, Number of Shares	3,827
Exercisable, Number of Shares	2,657
Available for future Grant, Number of Shares	1,434
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Rollforward]
Beginning balance, weighted average exercise price per share	$ 16.37	$ 14.74	$ 13.15
Granted, weighted average exercise price per share	23.15	26.63	22.36
Exercised, weighted average exercise price per share	12.30	13.67	12.16
Cancelled, weighted average exercise price per share	23.41	20.63	10.61
Ending balance, weighted average exercise price per share	17.44	$ 16.37	$ 14.74
Vested and expected to vest, weighted average exercise price per share	17.20
Exercisable, weighted average exercise price per share	$ 14.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Vested and Expected to Vest, Weighted Average Remaining Contractual Term	5 years 6 months 8 days
Exercisable, Weighted Average Remaining Contractual Term	4 years 1 month 28 days
Aggregate intrinsic value	$ 19,225
Vested and Expected to Vest, Aggregate Intrinsic Value	19,192
Exercisable, Aggregate Intrinsic Value	$ 18,503

Stock-Based Compensation - Su51

Stock-Based Compensation - Summary of Status of Stock Awards Activity (Detail) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Beginning Balance, Shares	402	454	522
Granted, Shares	171	145	74
Vested, Shares	(96)	(174)	(141)
Forfeited, Shares	(18)	(23)	(1)
Ending Balance, Shares	459	402	454
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Rollforward]
Beginning Balance, Weighted Average Grant Date Fair Value	$ 14.84	$ 16.22	$ 13.87
Granted, Weighted Average Grant Date Fair Value	22.79	25.73	23.53
Vested, Weighted Average Grant Date Fair Value	18.01	28.27	23.43
Forfeited, Weighted Average Grant Date Fair Value	22.87	18.19	15.26
Ending Balance, Weighted Average Grant Date Fair Value	$ 21.61	$ 14.84	$ 16.22

Commitments and Contingencies -

Commitments and Contingencies - Commitments for Minimum Rentals under Non-cancelable Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, 2015	$ 2,383
Operating Leases, 2016	1,885
Operating Leases, 2017	1,644
Operating Leases, 2018	1,669
Operating Leases, 2019	1,684
Operating Leases, Thereafter	1,971
Operating Leases, Minimum Payments, Total	11,236
Lease Obligation, 2015	922
Lease Obligation, 2016	931
Lease Obligation, 2017	940
Lease Obligation, 2018	950
Lease Obligation, 2019	959
Lease Obligation, Thereafter	1,079
Lease Obligation, Minimum Payments, Total	5,781
Less amount representing interest	(1,164)
Present value of lease obligation	4,617
Less current portion	(585)	$ (509)
Long-term lease obligation	$ 4,032

Commitments and Contingencies53

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended	12 Months Ended
	Dec. 31, 2013USD ($)ft²	Sep. 30, 2011USD ($)	Sep. 30, 2011USD ($)	Dec. 31, 2015USD ($)Lease	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)ft²	Apr. 01, 2011USD ($)
Sale Leaseback Transaction [Line Items]
Reimbursement Related To Research And Development Expense				$ 0	$ 400	$ 1,400
Rent expense under operating leases	$ 2,300			$ 2,300	3,300
Lease expiration year				2,022
Number of extension | Lease				2
Extend the lease options				5 years
Lease incentives for tenant improvements				$ 1,700
Facility sold				15,000
Capital contributed				3,800
Cash transaction, netting				$ 7,000
Partnership that acquired the facility				25.00%
Lease payments	$ 1,100			$ 1,100	1,100
Purchase commitments				4,000
Accrued in other current liabilities				6,999	8,043
Agreement for payments totaling							$ 29,500
Initial cash payments		$ 13,800
Fixed cash payment		$ 15,700
Contract value Discount			$ 1,000
One-time charge to cost of sales				700
Amortization expense				10,200	17,400	16,600
Company had royalty and license expenses relating to those agreements				$ 500	900	$ 1,000
San Diego [Member]
Sale Leaseback Transaction [Line Items]
Lease term period				Dec. 1, 2019
Number of extension | Lease				3
Extend the lease options				5 years
Amended terms				10 years
Property Subject to Operating Lease [Member]
Sale Leaseback Transaction [Line Items]
Area under new operating lease | ft²	30,000					30,000
Patented technology [Member]
Sale Leaseback Transaction [Line Items]
Assigned licensed technology				$ 28,800
License agreements [Member]
Sale Leaseback Transaction [Line Items]
Amortization expense	$ 8,000			700	8,000
Research and Development Collaboration Agreements [Member]
Sale Leaseback Transaction [Line Items]
Current commitments				4,200
Claims and litigation [Member]
Sale Leaseback Transaction [Line Items]
Accrued in other current liabilities				200	300
Research and Development Arrangement [Member]
Sale Leaseback Transaction [Line Items]
Milestone Payments Made Under Agreement				1,700	900
Bio Helix [Member]
Sale Leaseback Transaction [Line Items]
Payments for Royalties				100	49
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				0	$ 800
Andiatec Acquisition [Member]
Sale Leaseback Transaction [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				$ 67

Commitments and Contingencies C

Commitments and Contingencies Contingent Consideration (Acquisitions) (Details) $ in Thousands, € in Millions	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015EUR (€)	Aug. 31, 2013USD ($)	Aug. 31, 2013EUR (€)	May. 31, 2013USD ($)
Business Acquisition, Contingent Consideration [Line Items]
Payment On Acquisition Contingency	$ 129	$ 2,112	$ 947
Current portion of contingent consideration	1,286	733
Contingent consideration non-current portion	4,230	5,023
Andiatec Acquisition [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	67
Current portion of contingent consideration	0
Contingent consideration non-current portion	100
Bio Helix [Member]
Business Acquisition, Contingent Consideration [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	0	800
Contingent consideration							$ 13,000
Current portion of contingent consideration	1,300
Contingent consideration non-current portion		4,100
Maximum [Member] | Andiatec Acquisition [Member]
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration					$ 500	€ 0.5
Minimum [Member] | Bio Helix [Member]
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration							$ 5,000
Research and Development Arrangement [Member]
Business Acquisition, Contingent Consideration [Line Items]
Milestone Payments Made Under Agreement	1,700	$ 900
Research and Development Arrangement [Member] | Andiatec Acquisition [Member]
Business Acquisition, Contingent Consideration [Line Items]
Contingent consideration	$ 3,300			€ 3

Industry and Geographic Infor55

Industry and Geographic Information - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2015USD ($)Segment	Dec. 31, 2014USD ($)	Dec. 31, 2013
Revenue, Major Customer [Line Items]
Number of reportable segments | Segment	1
Customer Concentration Risk [Member] | Non-U.S. Customers [Member]
Revenue, Major Customer [Line Items]
Accounts receivable	$ 5.6	$ 5.5
Customer Concentration Risk [Member] | Sales [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	48.00%	48.00%	43.00%
Customer Concentration Risk [Member] | Sales [Member] | Non-U.S. Customers [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	14.00%	13.00%	13.00%
Credit Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Accounts receivable	$ 12	$ 23.7
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Minimum [Member]
Revenue, Major Customer [Line Items]
Percentage of risk concentration by major customer	10.00%	10.00%

Industry and Geographic Infor56

Industry and Geographic Information - Sales to Individual Customers in Excess of 10% of Total Revenue (Detail) - Sales [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue, Major Customer [Line Items]
Sales percentage	48.00%	48.00%	43.00%
Customer A [Member]
Revenue, Major Customer [Line Items]
Sales percentage	20.00%	19.00%	19.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Sales percentage	17.00%	18.00%	16.00%
Customer C [Member]
Revenue, Major Customer [Line Items]
Sales percentage	11.00%	11.00%	8.00%

Industry and Geographic Infor57

Industry and Geographic Information - Long-lived Assets (Excluding Intangible Assets) and Total Net Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total					$ 52,547					$ 52,547	$ 49,226
Total revenues	$ 52,412	$ 46,812	$ 35,204	$ 61,701	63,953	$ 41,193	$ 31,883	$ 47,129	$ 196,129	184,158	177,325
Federal [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total					52,426					52,426	49,052
Total revenues									168,809	159,845	154,626
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, Total					$ 121					121	174
Total revenues									$ 27,320	$ 24,313	$ 22,699

Industry and Geographic Infor58

Industry and Geographic Information - Consolidated Net Product Revenues by Disease State (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Revenues	$ 196,129	$ 184,158	$ 177,325
Infectious Disease [Member]
Segment Reporting Information [Line Items]
Revenues	141,857	130,416	128,079
Women's Health [Member]
Segment Reporting Information [Line Items]
Revenues	37,161	34,332	33,328
Gastrointestinal Disease [Member]
Segment Reporting Information [Line Items]
Revenues	7,224	7,414	6,622
Royalty, License Fees and Grant Revenue [Member]
Segment Reporting Information [Line Items]
Revenues	6,189	7,681	3,917
Other Disease [Member]
Segment Reporting Information [Line Items]
Revenues	$ 3,698	$ 4,315	$ 5,379

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Assets:
Total assets measured at fair value	$ 133,147
Liabilities:
Total liabilities measured at fair value	5,516	$ 5,756
Cash equivalents [Member]
Assets:
Total assets measured at fair value	133,147	3,057
Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value		5,756
Level 1 [Member]
Assets:
Total assets measured at fair value		3,057
Liabilities:
Total liabilities measured at fair value	0	0
Level 1 [Member] | Cash equivalents [Member]
Assets:
Total assets measured at fair value	133,147	3,057
Level 1 [Member] | Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	0	0
Level 2 [Member]
Assets:
Total assets measured at fair value	0	0
Liabilities:
Total liabilities measured at fair value	0	0
Level 2 [Member] | Cash equivalents [Member]
Assets:
Total assets measured at fair value	0	0
Level 2 [Member] | Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	0	0
Level 3 [Member]
Assets:
Total assets measured at fair value	0	0
Liabilities:
Total liabilities measured at fair value	5,516	5,756
Level 3 [Member] | Cash equivalents [Member]
Assets:
Total assets measured at fair value	0	0
Level 3 [Member] | Contingent consideration [Member]
Liabilities:
Total liabilities measured at fair value	$ 5,516	$ 5,756

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	$ 133,147,000
Amount outstanding under the Senior Credit Facility		$ 0	$ 0
Total liabilities measured at fair value	5,516,000	5,756,000
Cash equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	133,147,000	3,057,000
Contingent consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities measured at fair value		5,756,000
Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value		3,057,000
Total liabilities measured at fair value	0	0
Level 1 [Member] | Cash equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	133,147,000	3,057,000
Level 1 [Member] | Contingent consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities measured at fair value	0	0
Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	0	0
Total liabilities measured at fair value	0	0
Level 2 [Member] | Cash equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	0	0
Level 2 [Member] | Contingent consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities measured at fair value	0	0
Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	0	0
Total liabilities measured at fair value	5,516,000	5,756,000
Level 3 [Member] | Cash equivalents [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets measured at fair value	0	0
Level 3 [Member] | Contingent consideration [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total liabilities measured at fair value	$ 5,516,000	$ 5,756,000

Fair Value Measurement - Change

Fair Value Measurement - Changes in Estimated Fair Value of Contingent Consideration Liabilities (Detail) - Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ 5,756
Cash payments	(129)
Net gain recorded for fair value adjustments	(88)	$ (900)
Unrealized gain on foreign currency translation	(23)
Balance		$ 5,756
Contingent consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance	$ 5,516

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Compensation Related Costs [Abstract]
Pay contributed by employer	50.00%
Pay contributed by employee	6.00%
Contribution to 401 (K) Plan	$ 1.3	$ 1.1	$ 0.9

Impairment Loss (Details)

Impairment Loss (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Impairment loss		$ 0	$ 3,558	$ 0
Loss on contract termination		200
Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Impairment loss			$ 1,500
In Process Research and Development [Member]
Property, Plant and Equipment [Line Items]
Impairment loss	$ 1,600	0
Other Intangible Assets [Member]
Property, Plant and Equipment [Line Items]
Impairment loss		300
Project Stella [Member]
Property, Plant and Equipment [Line Items]
Impairment loss		$ 3,400

Selected Quarterly Financial 64

Selected Quarterly Financial Data (unaudited) - Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Total revenues	$ 52,412	$ 46,812	$ 35,204	$ 61,701	$ 63,953	$ 41,193	$ 31,883	$ 47,129	$ 196,129	$ 184,158	$ 177,325
Cost of sales (excludes amortization of intangible assets)	18,122	16,961	15,493	21,112	21,263	16,768	15,902	20,247	71,688	74,180	66,976
Gross profit	32,700	28,261	18,121	39,018	41,120	22,854	14,410	25,311
Total costs and expenses (1)	49,750	45,600	45,029	53,012	51,038	51,314	41,868	49,146	193,391	193,366	172,483
Net income (loss)	$ (377)	$ (762)	$ (8,931)	$ 3,991	$ 7,113	$ (5,767)	$ (6,908)	$ (1,512)	$ (6,079)	$ (7,074)	$ 7,390
Basic (loss) earnings per share	$ (0.01)	$ (0.02)	$ (0.26)	$ 0.12	$ 0.21	$ (0.17)	$ (0.20)	$ (0.04)	$ (0.18)	$ (0.21)	$ 0.22
Diluted net earnings (loss) per share	$ (0.01)	$ (0.02)	$ (0.26)	$ 0.11	$ 0.20	$ (0.17)	$ (0.20)	$ (0.04)	$ (0.18)	$ (0.21)	$ 0.21

Selected Quarterly Financial 65

Selected Quarterly Financial Data (unaudited) - Quarterly Financial Data (Footnote) (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
Income Statement [Abstract]
Amortization of intangible assets included in gross profit	$ 1.5	$ 1.6	$ 1.6	$ 1.6
Selling, General and Administrative expense			$ 0.3	$ 0.4	$ 0.4	$ 0.3	$ 0.4	$ 0.5

Consolidated Valuation and Qu66

Consolidated Valuation and Qualifying Accounts (Detail) - Allowance for Doubtful Accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning Balance	$ 8,221	$ 5,790	$ 4,955
Charges to costs and expenses	31,532	23,447	15,230
Ending Balance	7,488	8,221	5,790
Deductions	$ (32,265)	$ (21,016)	$ (14,395)